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Macrophages are key cellular components of the innate immunity, acting as the main player in the ﬁrst-line defence against the
pathogens and modulating homeostatic and inﬂammatory responses. Plasticity is a major feature of macrophages resulting in
extreme heterogeneity both in normal and in pathological conditions. Macrophages are not homogenous, and they are generally
categorized into two broad but distinct subsets as either classically activated (M1) or alternatively activated (M2). However,
macrophages represent a continuum of highly plastic eﬀector cells, resembling a spectrum of diverse phenotype states. Induction
of speciﬁc macrophage functions is closely related to the surrounding environment that acts as a relevant orchestrator of
macrophage functions. This phenomenon, termed polarization, results from cell/cell, cell/molecule interaction, governing
macrophage functionality within the hosting tissues. Here, we summarized relevant cellular and molecular mechanisms driving
macrophage polarization in “distant” pathological conditions, such as cancer, type 2 diabetes, atherosclerosis, and periodontitis
that share macrophage-driven inﬂammation as a key feature, playing their dual role as killers (M1-like) and/or builders
(M2-like). We also dissect the physio/pathological consequences related to macrophage polarization within selected chronic
inﬂammatory diseases, placing polarized macrophages as a relevant hallmark, putative biomarkers, and possible target for
prevention/therapy.
1. Introduction
Macrophages belong to the mononuclear phagocyte system
(MPS), a family of professional phagocytes that includes
monocyte and dendritic cells (DCs). Over the past few
decades, classiﬁcation of the cells within the MPS system has
generated considerable controversy given the diﬀerent, often
confusing, nomenclature to identify macrophages in diﬀerent
physio/pathological conditions as a consequence of their
plasticity, resulting in very diﬀerent phenotype/functions.
The ﬁrst open debate arises already in the deﬁnition of
macrophage cell of origin. The classic scenario of the MPS
stated that monocytes recruited from the periphery, under
the inﬂuence of speciﬁc tissue-local growth factors, developed
into macrophages. According to this scenario, macrophages
derive from hematopoietic progenitors of bone marrow that
diﬀerentiate under the inﬂuence of speciﬁc growth factors
within the hosting tissues [1]. These cells primarily enter the
blood as monocytes and further inﬁltrate tissues as macro-
phages, where they adapt to the local microenvironment to
play out speciﬁc functions, such Kupﬀer cells in the liver,
microglial cells in the brain [2], and mesangial cells in
the kidney [3].
This view has been completely reconsidered over the last
decade, and the ontogeny of macrophages has been totally
rewritten, based on genetic approaches of cell fate mapping.
New evidence demonstrated that macrophages can originate
from embryonic precursor cells that colonized developing
tissues before birth (foetal tissue macrophages) and that
tissue-resident macrophages have self-maintaining abilities
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in the adulthood. Murine models allow the deﬁnition of three
main sources for tissue-resident macrophages: (i) the yolk sac
in the embryo as a source for progenitor cells by primitive
hematopoiesis; (ii) the foetal liver, where the hematopoiesis
takes places, shifting form the yolk sac, and (iii) the bone
marrow that becomes the elicit hematopoietic centre in late
embryos and adult organisms [4–6]. Another intriguing sce-
nario, concerning the origin and persistence of macrophages,
has been proposed by Gomez et al. [7]. The model proposed
that resident macrophages, developing in the embryo inde-
pendently of the hematopoietic stem cell (HSC) compart-
ment [2, 8–11], still persist in adults and can coexist with
the so termed “passenger” leucocytes that include monocytes
and DCs, which originated from bone marrow HSCs and
myeloid progenitors [1, 12, 13].
The abundance of macrophages within tissues is ﬁnely
controlled through the axis colony-stimulating factor-1 or
macrophage-colony-stimulating factor (CSF-1 or M-CSF),
IL-34, and colony-stimulating factor-1 receptor (CSF-1R) [14].
It has been reported that recruited macrophages diﬀer
from the resident tissues in terms of transcriptional proﬁling.
Even if the term “macrophage activation” has been com-
monly used to describe macrophage activity in response to
diverse stimuli, several studies pointed out that the results
of cell activation deeply depend on the macrophage location
and on the stimulus that triggers their activation.
In vitro and in vivo studies have shown that the pheno-
typic heterogeneity of macrophages correlates with peculiar
functions speciﬁc to their local microenvironment [15] and
this plasticity enables the appropriate response to pathogen
or injury challenge.
Macrophage activation can be obtained in response to a
plethora of diverse stimuli, including microbial products,
damaged cells, activated lymphocytes, and inﬂammatory
cells, and can result in the acquisition of distinct functional
subsets undergoing diﬀerent phenotypic polarizations.
Macrophage plasticity and heterogeneity give rise to a
still opened debate, concerning the nomenclature to identify
cell subsets/subtypes undergoing in such diﬀerent pheno-
typic, functional (cytokine release), metabolic, regulatory
(versus other arms of innate and adaptive immunity)
rearrangements.
On the basis of the type-1/type-2 helper- T(h-) cell polar-
ization concept [16, 17], phenotypically polarized macro-
phages have been deﬁned according to two primary
activation states, termed classically activated M1 and alterna-
tively activated M2 (Figure 1(a)). M1 and M2 nomenclature
has been long and lastly employed to deﬁne the “supposed”
main subsets of macrophages, which originates in 2000 by
Mills et al. [18]. Basically, M1 and M2 responses exemplify
the opposing activities of killing (proinﬂammatory, “killer
M1”) and repairing (anti-inﬂammatory, “builder M2”) [19].
However, macrophage polarization in many physiologic
and pathologic conditions represents a continuum, involving
high plasticity and heterogeneity of these eﬀector cells, and
resemble mainly to a spectrum of distinct polarization states
that do not ﬁt to the oversimpliﬁed M1/M2 classiﬁcation.
Hence, in line with a consensus recommendation, we decide
to use “M1” to indicate only IFN-γ and LPS-driven
macrophage phenotypes and “M2” to refer to macrophage
phenotypes triggered only by IL 4 or IL 13. Furthermore,
we use “M1-like” to illustrate diverse signal-induced polari-
zation states that leads to cell cytotoxic function (killer) and
antitumour activities and “M2-like” in relation to distinct
phenotypes that share the functional capacity of repair,
inducing new vessels and remodelling (builder) in parallel
with tumour promotion and immunosuppressive ability
toward T-cell responses [20] (Figure 1(b)).
In a normal tissue, the ratio of M1-like/M2-like macro-
phages is highly regulated and increases during the inﬂam-
mation process [21]. Gene expression proﬁle analysis
showed that M1 macrophages can release high levels of pro-
inﬂammatory cytokines, including tumour necrosis factor-α
(TNF-α), CCL2 also known as monocyte chemoattractant
protein-1 (MCP-1), IL-6, inducible nitric oxide synthase
(iNOS), IL-1, IL-12, type I IFNs, CXCL1–3, CXCL5, and
CXCL8–10 [22]. On the contrary, M2 macrophages have
been demonstrated to express high levels of dectin-1, DC-
SIGN (CD209), mannose receptor (CD206), scavenger
receptor A, scavenger receptor B-1, CD163, CCR2, CXCR1,
and CXCR2 [23] and to produce a large amount of IL-10,
YM1, macrophage and granulocyte inducer-form 1 (MgI1),
and arginase-1, highlighting their relevance during tissue
remodelling and repair [24].
Macrophage polarization and functions are tightly reg-
ulated through the activation of several interconnected
pathways. Among all, the balance between activation of
STAT1 and STAT3/STAT6 has been demonstrated to play
a crucial role; indeed, the predominance of STAT1 activa-
tion promotes M1 macrophage polarization, resulting in
cytotoxic and proinﬂammatory functions. In contrast,
STAT3 and STAT6 activation by IL-4/IL-13 and IL-10 sig-
naling increases M2 macrophage polarization, associated
with active tolerance and tissue repairing [22]. Moreover,
the downstream eﬀector of STAT6 and KLF-4 promotes
M2 macrophage functions by suppressing the NF-κB/HIF-
1α-dependent transcription. IL-10 promotes M2 polarization
inducing p50 NF-κB homodimer, c-Maf, and STAT3 activi-
ties. In addition, IL-4 induces c-Myc that activates the IRF4
axis that inhibits IRF5-mediated M1 polarization, resulting
in the M2 promotion [22]. Bouhlel et al. also demonstrated
the relevance of PPAR-γ (peroxisome proliferator-activated
receptor gamma) in skewing human monocytes toward an
anti-inﬂammatory M2 phenotype. Indeed, the authors
showed that PPAR-γ is highly upregulated in M2 macro-
phages and PPAR-γ agonists have been demonstrated to
induce directly M2-like diﬀerentiation of monocytes in vivo
and in vitro [25].
In the past decade, a novel class of small noncoding
RNAs, termed microRNAs (miRs), has emerged as impor-
tant regulators in biological processes. Accumulating evi-
dence suggest a relevant role for several miRs in the
polarization process (Figure 1(a)). In particular, miR-155
and miR-223 are involved in modulating macrophage activa-
tion state by targeting SOCS1, C/EBP (a hallmark ofM2mac-
rophages), and Pknox1 [26]. Overexpression or silencing of
miR-155 has been demonstrated to drive macrophages to
M1 or M2 phenotype, respectively, conﬁrming that miR-155
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Figure 1: Continued.
3Journal of Immunology Research
M(IL-10)
TGFBR2, IL-17RB,
CD200R
IL-4RA
Socs3
GATA3, IRF4,
Socs1
ID3, RGS1,
pSMAD2+
IRF5
pSTAT1+++,
IRF5, IRF1
pSTAT1+++,
IRF5
IDO1,
KYNU
IDO1,
KYNU
MRC1, STAB1
MARCO, CD163
IL-10
IL-4
TGFB1, MMP1,
MMP12, TG,
FI3A1
LPS
M( − )
GC
M(GC)
F13A1
STAB1, MARCO,
CD163
TGFBR2,
ADORA3
CCL4, CC13,
CCL17, CCL18
§
§
§
§
§
§
TGFBR2, IL-17RB,
ALOXSAP
M(LPS)
GC  + TGF- 훽 
LPS + IFN- 훾
IFN- 훾
M(IFN- 훾)
M(GC  + TG F-훽 )
M(LPS  +  IFN- 훾)
M1
PTX3
TNF, IL-6, IL-1B
MMP9
CCL5, CXCL9,
CXCL10, CXCL11
TNF, IL-6, IL-1B,
IL-12A, IL-12B, IL-23A
CCL18-ve
M(IL-4)
M2
(b)
Figure 1: Past and new concept in macrophage polarization. (a) Schematic overview of the diﬀerent stimuli that can induce the diverse
macrophage polarization state. M1: classically activated phenotype; M2: alternatively activated macrophages; ATM: adipose tissue-derived
macrophages; Mox: atherosclerosis-associated macrophages; TAMs: tumour-associated macrophages. (b) The polarization landscape of
macrophages. According to the diﬀerent stimulation conditions, macrophages can acquire peculiar M1 or M2 phenotype, governed by the
diﬀerent surface antigen expressions, including scavenger receptors, chemokine, matrix-associated protein and cytokine release, and
diﬀerent patterns of transcription factors and metabolic pathway activated. The driver stimuli include IL-4, IL-10, glucocorticoids (GC)
with TGF-β, glucocorticoids alone, LPS, LPS and IFN-γ, and IFN-γ alone.
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plays a central role in regulating Akt-dependent M1/M2
polarization of macrophages. It has been also shown that
miR-155 downregulates the expression of IL-13Rα1, sup-
pressing the polarization toward M2 phenotype [27, 28].
Some studies have observed that let-7c was expressed at a
higher level in M2 macrophages than in M1 macrophages.
Accordingly, the upregulation of let-7c in macrophages
diminishedM1phenotype and promotesM2polarization tar-
geting C/EBP-d [29, 30]. miR-146, miR-125b, miR-155, and
miR-9 can inhibit TLR4/IL-1R signaling by regulating
IRAK-1, TRAF6, IKKe, p50 NF-κB, and TNF-α [29]. Further,
miR-17, miR-20a, and miR-106a reduce the expression level
of the signal regulatory protein (SIRPa), an important mac-
rophage diﬀerentiation-related marker. miR-98 and miR-21
downregulate the expression of inﬂammatory genes in
monocytes and macrophages via controlling IL-10 level [31].
Emerging data have demonstrated that epigenetic mech-
anisms, including chromatin remodelling, DNA methylation
(DNAm), histone modiﬁcations, and regulation of target
gene expression, are also involved in the orchestration of
macrophage polarization in response to local environmental
signals [22, 32, 33]. M1 and M2 macrophages have been
shown to express diﬀerent levels of DNA methyltransferase
(DNMT) 1, 3a, and b that are associated with gene silencing
[34]. DNMT1 drives the M1 polarization in atherosclerosis
by directly targeting the promoter of PPAR-γ in macro-
phages [35]. The DNMT3b binding of the promoter of
PPAR-γ contributes to the M1 phenotype in adipose tissue
during inﬂammatory process [33].
Lund et al. demonstrated that atherogenic lipoproteins
can promote global DNA hypermethylation in monocyte
[36]. Thus, DNMT inhibition or knockdown could decrease
theM1 polarization, providing novel strategies for atheroscle-
rosis prevention and therapy. Accordingly, the treatment
with 5-aza-2-deoxycytidine (decitabine), a recognized inhib-
itor of DNMTs, results in an increased M2 polarization
induced by the inhibition of the PPAR-γ promoter, which
in turn prevents obesity-induced inﬂammation, atherosclero-
sis, and insulin resistance [37, 38]. DNMT3a and DNMT3al
expression levels have been shown to be increased signiﬁ-
cantly in M2 compared to M1 macrophages, and this is asso-
ciated with AMPK signaling [33]. On the contrary, DNMT3b
was signiﬁcantly lower in M2 compared with M1 adipose
macrophages [39]. Histone H3 and H4 acetylations were
found to be toughly associated with the maturation of human
monocytes [40]. M1 polarization induced by IFN-γ increases
histone H4 acetylation at the TNF-α promoter throughout
the ERK and p38 mitogen-activated protein kinase (MAPK)
signaling pathways [41]. STAT3 and MAPK activation and
the simultaneous acetylation of histones H3 and H4 on the
SOCS-3 promoter suppress the inﬂammatory responses in
microglial cells and promote M2 polarization [42]. Histone
deacetylase 3- (HDAC3-) deﬁcient macrophages showed a
decreased expression of IFN-β and Cox-1 showing an M2-
like phenotype and thereby ameliorate many inﬂammatory
diseases, such as pulmonary inﬂammation [43–45].
Such heterogeneity in macrophage phenotypes and func-
tions generated the still open questions of whether they act as
killers or builders. During inﬂammation, macrophages drive
in the autoregulatory loop characterizing this process, as they
release a wide range of biologically active molecules which
participated in both detrimental (killers) and beneﬁcial
(builders) in inﬂammation [46–48]. Therefore, inﬂammation
stands as the typical environmental setting where macro-
phages show their “Janus” behaviour [46–48]. During the
ﬁrst events occurring during inﬂammation, macrophages are
endowed to kill/remove pathogens and damaged cells, while
at the end of the inﬂammatory process, termed resolution of
inﬂammation, macrophages act as builders that promote
damaged tissue regeneration and return to homeostasis
[49–51]. Since inﬂammation represents a shared hallmark
from diverse chronic diseases and direct involvement in
insurgence and progression of these conditions, here, we
discuss whether macrophages can act as killers or builders
within the inﬂammatory landscape of selected and appar-
ently “distant” pathologic conditions.
2. Macrophages in Cancer: Killers or Builders?
Macrophages represent the most abundant tumour inﬁl-
trating inﬂammatory cells [52, 53]. Reﬂecting their extreme
plasticity within healthy tissues, macrophages inﬁltrating
tumours can acquire distinct phenotype and functions result-
ing in the attenuation of antitumour activity and induction of
tumour-supporting functions and have been deﬁned as
tumour-associated macrophages (TAMs) with M2-like fea-
tures (Figure 2). However, in the initial phases of carcino-
genesis, macrophages can act as protective killer cells,
cooperating with T lymphocytes in the control of early
proliferating cancer cells in the immunoediting process
[54]. Instead, in developing tumours, compelling evidence
indicate that subverted macrophages or TAMs exert a major
role in driving tumour progression by diﬀerent mechanisms
and pathways, depending on the types of tumour, tissues,
and inﬂammatory mediators. The builder option of macro-
phages in the tumour microenvironment (TME) can lie to
conditions in which a chronic nonresolving inﬂammation is
established, a feature that has been deﬁned a hallmark of can-
cer [55] and that points out TAMs as key inﬂammatory
mediators able to link chronic inﬂammation with cancer
development and progression [56, 57].
Among soluble factors that mediate their displacement,
there are CCL2, CCL5, CSF-1, VEGF, and complement ele-
ments, which are often produced by the cancer cells and stro-
mal cells in the TME. Moreover, some TAMs can derive from
diﬀerentiation of monocytic myeloid-derived suppressor
cells (M-MDSCs) via upregulation of CD45 tyrosine phos-
phatase activity in response to tumour hypoxia and following
downregulation of STAT3 [58].
Tumour promoting or builder activities exerted by
TAMs have been demonstrated by several studies. Elevated
TAM inﬁltration has been correlated with worse clinical
outcome in most malignant tumours, such as breast, cervi-
cal, ovarian, prostate, and thyroid cancers; Hodgkin’s lym-
phoma; hepatocellular carcinoma; lung carcinoma; and
cutaneous melanoma [56, 59–65]. In contrast to these ﬁnd-
ings, some reports have instead highlighted that tumour inﬁl-
trating macrophages correlated to increased survival in
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colorectal, prostatic, and lung cancer patients [66–70]. The
main builder features of TAM include the ability to support
tumour angiogenesis as well as lymphangiogenesis, to
increase the breakdown of extracellular matrix, to promote
tumour cell invasion and migration, and to suppress the anti-
tumour immune responses [56, 62, 71, 72]. These functions
are shared with M2-like macrophages that, in a physiological
context, are induced during vascular and matrix remodelling,
necessary for damage resolution [73–77].
TAM inﬁltrate is also associated with the onset of resis-
tance to diﬀerent chemotherapeutic agents through the
activation of diverse pathways. In breast cancers, TAMs can
induce IL-10/STAT3/Bcl-2 signaling, leading to an inhibition
of apoptosis upon paclitaxel treatment [78]. In advanced
lung adenocarcinomas, TAMs are also reported to decrease
the responsiveness to target therapy based on the epidermal
growth factor receptor tyrosine kinase inhibitors [79].
M2-like TAMs support tumour growth directly by pro-
ducing cytokines able to stimulate the proliferation of
tumour cells or indirectly, by fostering endothelial cell (EC)
proliferation and angiogenesis (Figure 2). It has been
reported that the growth of subcutaneous Lewis lung tumour
is impaired in the CSF-1-deﬁcient and macrophage-deﬁcient
mice [80]. Furthermore, the treatment of tumour-bearing
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Figure 2: Macrophage polarization in tumour progression. Macrophage recruitment in tumours and their polarization are regulated by
several factors. Among all, hypoxia can induce the diﬀerentiation of monocytic myeloid-derived suppressor cells (M-MDSCs) via
upregulation of CD45 tyrosine phosphatase activity (1). Further, soluble factors, such as CCL2 and CCL5 that are produced by the cancer
cells and stroma cells, can increase macrophage inﬁltrate (2). In the TME, inﬁltrating associated to tumours (TAM/M2-like macrophages)
can orchestrate tumour progression by several mechanisms including the release of cytokine, chemokines, and tissue remodelling proteins.
Hypoxia increases the expression of CXCRs in TAMs and promotes tumour angiogenesis by enhancing the production of VEGF, TNF-α,
bFGF, IL-8, TP, and Sema4D that can induce endothelial cell proliferation, sprouting and migration, tube formation, and maturation of
new vessel, followed by its stabilization by attaching mural cells (A). TAMs can regulate the extracellular matrix degradation by producing
diﬀerent types of enzymes and proteases, such as matrix metalloproteinases (MMPs), in particular MMP2, MMP9, plasmin, urokinase
plasminogen activator (uPA) and cathepsins acting on connective tissue surrounding the tumour, and allow tumour cells to detach from
the mass of origin and to disseminate, leading to the formation of distant metastases (B).
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mice with recombinant CSF-1 reestablished the tumour
growth, indicating a role for macrophages in tumour growth.
TAMs can produce IL-6, whose release impacts on cell prolif-
eration by a STAT3-dependent mechanism. Inhibition of
STAT3 signaling blocks the antiapoptotic activity of IL-6 in
human liver cancer cells [81]. TAMs are lower producers of
TNF-α, resulting in enhanced tumour growth. Hypoxia sig-
niﬁcantly impacts on the TAM tumour cell interaction that
induces the expression of CXCR4 and its ligand, CXCL12
(SDF-1), further supporting tumour cell dissemination and
angiogenesis [82]. The number of TAMs within a tumour
has been positively correlated with its metastatic potential,
suggesting a role for TAMs in the distant dispersion of
tumour cells [52, 83, 84]. By producing diﬀerent types of
enzymes and proteases, such as matrix metalloproteinases
(MMPs), in particular MMP2 and MMP9, plasmin, uroki-
nase plasminogen activator (uPA), and cathepsins [85–87]
(Figure 2), TAMs can regulate the degradation of the extra-
cellular matrix (ECM) and dictate tumour invasion and the
metastatic process [19]. These factors act by relaxing the con-
nective tissue surrounding the tumour, allowing tumour cells
to detach from the mass of origin and to disseminate, leading
to the formation of distant metastases.
TAMs sustain tumour angiogenesis by producing
VEGFA (VEGF), the master growth factor involved in the
angiogenic process. Besides VEGF, TAMs release a panel of
proangiogenic factors which include TNF-α, basic ﬁbroblast
growth factor (bFGF), CXCL8/IL-8, thymidine phosphory-
lase (TP), adrenomedullin (ADM), and semaphorin 4D
(Sema4D) [88–91] (Figure 2). These factors released by
TAMs act by inducing endothelial cell proliferation, sprout-
ing and migration of ECs into the tumour, tube formation,
and maturation of new vessel, followed by its stabilization
by attaching mural cells [92].
It has been recently reported that the expression of
Sema3A from tumour cells is able to promote TAM accumu-
lation inside the tumour, particularly in the avascular areas
and required neuropilin-1 (NRP-1)-signaling cascade [93].
Macrophages are not only critical regulators of angiogenesis,
but also crucial participants in lymphangiogenesis via VEGFC
and VEGFD release, both in inﬂammatory settings and in
tumour progression [94]. Thus, TAM-derived factors can link
tumour angiogenesis and lymphangiogenesis [95–97].
Among TAMs, a relevant proangiogenic monocyte/
macrophage subset, characterized by some distinctive fea-
tures, has been further identiﬁed. These macrophages can
express the angiopoietin receptor Tie2, termed TEMs
(Tie2-expressing macrophages), and are closely associated
with the vasculature [98, 99]. These cells have been impli-
cated in the interference and in the resistance of action of
antiangiogenic therapeutics, in particular vascular disrupt-
ing agents, and experimental data support the notion that
inhibition of TEMs can foster antiangiogenic treatments
with higher inhibition of angiogenesis and tumour spread-
ing [100, 101].
Apart from their extreme plasticity, TAMs also sustain an
immunosuppressive milieu aiding tumours to escape from
immune surveillance [102]. TAM contribution to tumour
progression acts also through synergistic interaction with
other arms of the innate and adaptive immunity [46–48,
103] within the immunosuppressive TME. TAMs can inter-
act with MDSCs, neutrophils, and DCs [104, 105]. TAMs
also orchestrate the recruitment of T regulatory cells, by
secreting CCL20 [106, 107] and CCL22 [108], and their acti-
vation through a bidirectional interaction by the release of
IL-10 and TGF-β [107, 109–111].
Moreover, TAMs represent an important factor for the
establishment of the premetastatic niche [112–116].
Diﬀerent therapeutic strategies have been developed to
target TAM physiology with encouraging preclinical and
clinical results, either by blocking their tumour recruitment
and functions or by redirecting their features to antitumour
eﬀector activities [57, 81, 117–121]. In several preclinical
experimental models, including prostate, breast, and lung
cancer and melanoma, the speciﬁc inhibition by antibodies
of CCL2 has proven its promising eﬀects, and when they
are delivered in combination with chemotherapy shown
enhancement of the eﬀectiveness of treatment [122, 123].
However, though in a mouse model of breast cancer, it has
been reported that a rebound eﬀect following inhibition of
CCL2 pathway resulted in the recruitment of monocytes/
macrophages into the tumour and enhancement of lung
metastasis [124]; diﬀerent antibodies targeting CCL2 have
been entered phase I and II clinical trials. Regarding the
CCL5-CCR5 axis blocking strategies, a CCR5 antagonist
has been approved as a treatment for patients with liver
metastases of advanced refractory colorectal cancers and pre-
liminary results indicated that this approach can lead to clin-
ical responses [125]. Another interesting TAM-speciﬁc
therapeutic treatment involves interferences with the CSF-
1-CSF-1R axis, and in particular the receptor tyrosine kinase
CSF-1R. Several compound and antibody inhibitors have
been developed and evaluated in preclinical models and in
patients with diﬀerent types of cancer [120]. Important clin-
ical regressions were obtained from patients with diﬀuse-type
tenosynovial giant-cell tumour, which experienced CSF-1R
tumour overexpression [120]. Interestingly, in a mouse glio-
blastoma multiforme model, CSF-1R blockade did not aﬀect
the TAM numbers but instead the M2-like TAM polariza-
tion, which is associated with the block of glioma progression
and improvement of survival [119]. Also, bisphosphonates,
usually used to treat osteoporosis and to prevent bone
metastases-related complications, can be used to target mac-
rophages in the tumour context, although their cytotoxic
eﬀects have been illustrated initially toward osteoclasts
[126]. Combination chemotherapy or hormonal therapy
with bisphosphonates in diﬀerent types of tumour has shown
clinical synergistic eﬀects, in particular in postmenopausal
women with breast cancer [127]. Another encouraging
therapeutic strategy is related to agonistic anti-CD40 anti-
body and gemcitabine in pancreatic ductal adenocarcinoma
patients. This approach revealed clinical responses and
importantly demonstrated that in treated mice the CD40
agonist approach is responsible for reeducation of M2-like
TAM toward an M1-like phenotype and of eﬀective anti-
tumour responses [128, 129]. Finally, a recently identiﬁed
compound that found application in soft tissue sarcomas
and ovarian cancer patients is trabectedin, which induces
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selective TRAIL-dependent apoptosis of monocytes, macro-
phages, and M-MDSCs in the blood, spleens, and tumours
with reduction of TAMnumbers and angiogenesis [130, 131].
3. Macrophages in Type 2 Diabetes:
Killers or Builders?
Type 2 diabetes (T2D) is a metabolic disorder, and its inci-
dence has increased signiﬁcantly in recent years. T2D is char-
acterized by a peripheral resistance to the action of insulin
and a failure of beta cells to compensate, leading to hypergly-
caemia. It is now widely accepted that obesity increases the
risk of T2D by inducing a chronic low-grade inﬂammation
[132] and progression in local adipose tissue.
Accumulating evidence supports a role for tissue macro-
phages in a broad spectrum of inﬂammatory conditions
[133], including obesity-associated metabolic diseases, such
as insulin resistance and T2D [68, 134].
Macrophages together with other immune cells account
almost 10% of the normal adipose tissue and play a key role
in maintaining homeostasis. However, diet-induced obesity
compromises homeostasis, resulting in an increased inﬁltra-
tion of macrophages representing up to 50% of the cells in
adipose tissue [135, 136].
Several studies have established the crucial role of
macrophage polarization in the development of T2D. The
M1/M2-like polarization of tissue-destructive (killers) versus
tissue-reparative (builders) macrophages is of great interest
in clinical strategies because of their role in β-cell prolifera-
tion [137]. Recent evidence demonstrate that the high plas-
ticity and phenotypic diversity of macrophages promote the
cross-talk between β-cells, non-β endocrine cells, endothelial
cells, mesenchymal cells, and other circulation-derived blood
cells [138–140]. Builder-M2-like macrophages regulate β-cell
proliferation through the release of a variety of trophic
factors such as TGF-β1, which directly induce upregula-
tion of SMAD7 in β-cells. SMAD7 in turn promotes β-cell
proliferation by increasing CyclinD1 and CyclinD2 and by
inducing nuclear exclusion of p27 [141] (Figure 3). In
addition, M2-like macrophages also secrete Wnt ligands,
thus activating the Wnt signaling pathway, and β-catenin,
supporting β-cell replication [138] (Figure 3). Conversely,
only a few studies investigating the polarization state of
macrophages in pancreatic microenvironment have been
described in literature [16–19], where an overall increase
of macrophages/islets has been detected by immunohisto-
chemistry. Eguchi et al. [142, 143] showed that Ly6c+
M1 macrophage was expanded in the diabetic mouse islet.
Ly6c+-killer-M1 macrophage has been shown to secrete
IL-1β, resulting in potent inhibition of insulin secretion,
followed by islet destruction (Figure 3). The use of IL-1R
antagonists and anti-IL-1β-neutralizing antibodies was
able to abolish these eﬀects on pancreatic islets [21–24].
Several studies in T2D have shown that M1-like macro-
phages resulted in increased inﬂammation, obesity, and insu-
lin resistance, while M2-like macrophages are associated with
a reduction in both obesity and insulin resistance [144]. M2-
like macrophages are reported to not only suppress inﬂam-
matory cytokine IL-10 [145] but also provide a niche for
preadipocytes to keep the number and quality of them, thus
maintaining insulin sensitivity [146].
These data clearly suggest that macrophages play a
nonredundant role in the pathogenesis of T2D [147]. An
important aspect of diabetes prevention is a better under-
standing of the underlying mechanisms behind obesity-
induced visceral adipose tissue inﬂammation, crucial for
the development of T2D.
Obesity is associated with the accumulation of proinﬂam-
matory cells in visceral adipose tissue, which is an important
underlying cause of insulin resistance and progression to
T2D [148–150]. Establishing the initiating events leading to
the switch from an anti-inﬂammatory M2-like state to M1-
like phenotype remains elusive.
Recent studies show that obesity-induced adipocyte
hypertrophy results in upregulated surface expression of
stress markers. Adipose stress is detected by local sentinels,
such as NK cells and CD8+ T cells, which produce IFN-γ,
driving M1-like adipose tissue macrophage (ATM) polariza-
tion [148–150]. Adipocyte hypertrophy has been reported to
create hypoxic area and activates hypoxia-inducible factor-1,
which induces inﬂammatory cytokines and suppresses
preadipocyte-related angiogenesis and causes insulin resis-
tance [151].
Normal adipose tissue macrophages phenotypically
resemble the alternatively activated M2-like phenotype,
expressing the mannose receptor, the CD206 surface antigen,
and releasing Arg-1 and IL-10. In contrast, diet-induced obe-
sity leads to a shift toward an M1 classically activated macro-
phage, characterized by the F4/80, CD11b, and CD11c
expression [152] (Figure 3).
Low-grade inﬂammation in this setting is mediated by
the polarization of recruited and resident macrophages to
the M1-like phenotype in tissues, such as liver and adipose
tissues [153, 154]. In contrast, M2 macrophage activation
appears to protect against obesity-associated inﬂammation
and insulin resistance [155, 156]. Several cytokines and che-
mokines, such as CCL2, interleukin IL-6 and IL-1β, macro-
phage migration inhibitory factor (MIF), and TNF-α, can
be released by both adipocytes and macrophages [157, 158].
Macrophages within adipose tissue are recruited from the
bone marrow and are characterized by a wide panel of factors
that track with the degree of obesity [136, 159, 160]. Indeed,
the paracrine as far as the endocrine activity was exerted by
the proinﬂammatory cytokines, including TNF-α, IL-6, and
IL-1β released by ATMs can induce decreased insulin sensi-
tivity through the activation of Jun N-terminal kinase (JNK),
inhibitor of IKκB (IKK-β), and other serine kinases in insulin
target cells [161, 162].
The unbalance in the ratio between M1-like and M2-like
adipose macrophages has been considered to be directly
related to the development of insulin resistance [21, 149].
Insulin resistance resulted from a transition in macrophage
polarization from the M2-like activation state, induced by
STAT6 activation and PPAR, to a classic M1-like activation
state, further driven by NF-κB, AP1, and other related fac-
tors [163–165].
The network of molecular mediators that regulate M2
polarization in response to hypermetabolism is not fully
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understood, but peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC-1α) and PPAR-γ target
genes, such as arginase-1 and CD36, are implicated in this
process. PPAR-γ has been proven to be essential for mac-
rophage M2 polarization with the function of anti-
inﬂammation and associated with metabolic dysfunction
[145, 156, 166]. PPAR-γ was found to be a miR-130b tar-
get gene in regulating macrophage polarization insulin
tolerance via repression of PPAR-γ [167]. Several studies
have shown that PPAR-γ interacts with NF-κB, in the
modulation of macrophage polarization. PPAR-γ blocked
the proinﬂammatory pathway of NF-κB and inhibited the
expression of relative factors, such as TNF-α [168].
Further, it was shown that IL-6 acts as a Th2-builder
cytokine in obesity by stimulating M2-like polarization and
local ATM proliferation, presumably due to upregulation of
Adipose tissue
Islet destruction
M2-like
A
D
C
IL-1훽Wnt ligands
JNK
Insulin
resistance
IKK-훽
TNF-훼, IL-6,
IL-1훽
ATM
TGF-훽1
훽-Cell proliferation
SMAD7
CyclinD1 CyclinD2
Wnt
Wnt ligands
M1-like
B
miR-223
Pknox1
훽-catenin
TGF-훽1
TGF-훽-R
P27
Figure 3: Macrophage polarization in type 2 diabetes. Macrophage within pancreatic tissues can be switched toward diﬀerent functionalities
according to the environment stimuli. M2-like macrophage supports B-cell proliferation by several trophic factors like TGF-β1 which directly
induce upregulation of SMAD7 and increases of cyclinD1, cyclinD2, and p27 (A). Moreover, M2-like macrophages release Wnt ligands, thus
activating the Wnt signaling pathway, and β-catenin, supporting β-cell replication (B). M1-like macrophage in pancreatic tissues can secrete
IL-1b, inhibiting insulin secretion, followed by islet destruction (C). Adipose-derived macrophages (ATM) can release proinﬂammatory
cytokines, including TNF-α, IL-6, and IL-1β that decrease insulin sensitivity through the activation of Jun N-terminal kinase (JNK),
inhibitor of IKκB kinase (IKK-β), and other serine kinases in insulin target cells (D).
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the IL-4 receptor α [169]. Recently, it has been reported that
adenosine monophosphate kinase (AMPK) β1 plays an
important role in protecting macrophages from inﬂamma-
tion under high lipid exposure resulting in a modulation of
obesity-induced insulin resistance (Figure 3). Genetic dele-
tion of the AMPK β1 subunit in mice reduced macrophage
AMPK activity, acetyl-CoA carboxylase phosphorylation,
and mitochondrial content, resulting in reduced rates of fatty
acid oxidation [170].
Inhibition of proinﬂammatory cytokines and chemo-
kines, such as TNF-α, IL-1β, IL-6, and CCL2, may reduce adi-
pose tissue inﬂammation and insulin resistance [147, 171,
172]. For instance, several studies have demonstrated that
treatment with neutralizing IL-1β antibody or blockage of
IL-1β signaling improved glycaemic control in diet-induced
obese mice and insulin sensitivity in patients with T2D
[173–176]. Other ﬁndings suggest that the CCL2-CCR2 sig-
naling pathway disruption reduces adipose tissue macro-
phage content ameliorating insulin resistance and improves
insulin sensitivity [160, 177]. CCL2 knockout mice receiving
intact monocytes or mice receiving CCR2-deﬁcient mono-
cytes were both protected from the accumulation of macro-
phages in adipose tissue and the liver. [178] So far, targeting
the CCL2-CCR2 signaling pathway may provide the basis
for the development of novel therapies against T2D. In vivo
studies have shown that circulating levels of free fatty acid
(FFA) promote the generation of M1 macrophages via TLR4
signaling in adipocytes andmacrophages in the setting of obe-
sity [179–181]. In this context, adipose tissue inﬂammation is
aggravated by the secretion of TNF-α, which in turn increases
lipolysis leading to further production of FFAs establishing a
vicious circle. Resistin is another potential target to combat
insulin resistance or T2D. In fact, resistin induction which
in turn stimulates secretion of several proinﬂammatory cyto-
kines by increased inﬁltration of macrophages causes
inﬂammation-induced insulin resistance [182–184].
Several phase II and III clinical trials have been initiated
to inhibit key immunological processes of adipose tissue
inﬂammation in T2D patients, such as NF-κB signaling, IL-
1β function, or arachidonic acid metabolism, with promising
results [148].
A shift in the polarization of adipose tissue macrophages
from an M2-like state to an M-like proinﬂammatory state
resulting in insulin resistance favours inﬂammation and
insulin resistance [145]. Thus, targeting of inﬂammatory
M1/M2-like polarization process of obese patients appears
to be a promising future strategy for prophylaxis against dia-
betes development. For instance, adipose tissue macrophages
from CCR2 knockout mice are polarized to the M2-like mac-
rophages, even after obesity and CCR2 knockout mice were
found to be protected from diet-induced insulin resistance
[145, 160]. Furthermore, it has been shown that inhibition
of IL-10 secreted by M2-like macrophages enhances the
impairment of insulin signaling conﬁrming its protective role
in T2D [185].
Insulin-sensitizing thiazolidinediones (TZDs), clinically
used for T2D patients [186], target the PPAR-γ that plays a
key role in the maturation of M2-like macrophage and insu-
lin sensitivity. PPAR-γ deletion prevents polarization of the
monocyte/macrophage to the M2-like phenotype, and
PPAR-γ-deﬁcient mice exhibit glucose intolerance and insu-
lin resistance [187]. Therefore, existing and future drug
mechanisms may be involved in modulating the phenotypi-
cal and functional features of macrophages. For instance,
metformin is a drug widely used to treat T2D, to decrease
insulin resistance; it has been proposed that the beneﬁt may
result, at least in part, from modulating macrophage dif-
ferentiation and polarization [188, 189]. How metformin
can modulate the diﬀerentiation of Ly6C monocytes into
M2-like macrophages remains the subject of ongoing inter-
esting studies. In addition to glucose-lowering drugs, T2D
patients are typically treated with low-dose aspirin (acetylsa-
licylic acid) that has oﬀ-target anti-inﬂammatory properties.
Aspirin exerts its anti-inﬂammatory eﬀects via inhibition of
cyclooxygenase and a subsequent decrease in the proinﬂam-
matory prostaglandins [190]. Recently, it has been demon-
strated that aspirin-triggered resolvin D1 into a degradable
biomaterial after injury was able to signiﬁcantly increase
the accumulation of anti-inﬂammatory monocytes and
M2-like macrophages while limiting the inﬁltration of
neutrophils and increase proregenerative immune subpop-
ulations [191].
Incretin-based treatments and the cannabinoid 1 recep-
tor (CB1) blocker rimonabant have anti-inﬂammatory eﬀects
and may protect the pancreatic islets from IL-1β-driven.
However, this anorectic antiobesity and glucose-lowering
drug had also psychiatric side eﬀects [164, 192, 193].
Several studies highlight the role of miRs as key regula-
tors of cell fate determination and signiﬁcant contributors
to the pathogenesis of complex diseases, such as inﬂamma-
tory responses and T2D [194]. It was found that miR-223
inhibits Pknox1, suppressing proinﬂammatory activation of
macrophages, and protects against diet-induced adipose tis-
sue inﬂammatory response and systemic insulin resistance
[195]; miR-130b was found to be a novel regulator of macro-
phage polarization via repression of PPAR-γ and a promising
target for T2D therapy [167]; miR-27a was also proposed as a
target of intervention for inﬂammation and insulin resistance
in obesity [196].
In summary, M1/M2-like macrophage polarization and
switching hold the key to the regulation of insulin sensitivity
and T2D. Macrophage polarization toward the alternative
M2-like phenotype may play a preventive role and also be a
novel and useful strategy for the treatment of insulin resis-
tance and T2D.
Novel macrophage-targeted strategies that are both
tissue-speciﬁc and disease-speciﬁc hold a promise for the
future management of the chronic inﬂammatory disorders
that were covered in this review.
4. Macrophages in Atherosclerosis:
Killers or Builders?
Atherosclerosis is a chronic inﬂammatory disease driven by
an imbalance in lipid metabolism and a maladaptive immune
response [197]. This disease is characterized by the accumu-
lation of lipids in large- and medium-sized arteries forming
plaque deposits that block the ﬂow of the blood. Several
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factors have been correlated with the development of athero-
sclerotic diseases, among which the elevated low-density
lipoprotein (LDL) cholesterol, hypertension, obesity, and
both T2D and T1D. The accumulation of LDL promotes
the recruitment of monocytes that lead to the formation of
the atherosclerotic plaques [198]. Further, the exposure to
CSF-1 and the uptake of oxidized LDL (ox-LDL) induce
monocyte diﬀerentiation into macrophage and results in
foam cell formation with the proliferation of smooth muscle
cells [199]. The scavenger receptors lead the ox-LDL recogni-
tion, and the intracellular cholesterol is metabolized and
transported to exogenous acceptors, such as high-density
lipoprotein, through eﬄux proteins, such as ATP-binding
cassette transporters [200] (Figure 4).
Macrophage apoptosis has been observed in patients with
defects in the Acyl-CoA:cholesterol acyltransferase (ACAT),
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Figure 4: Macrophage polarization in atherosclerosis. Macrophages are crucial players involved in the atherosclerosis development due to
their ability to regulate cholesterol eﬄux. In this context, the upregulation of LXRs in M2 macrophages has been found to exert a
protective role. Indeed, LRXs reduce peripheral tissue excess cholesterol that is returned to the liver by releasing HDL in the plasma (A).
Apart from M1 and M2 polarization, a third macrophage state has been described in the atherosclerosis context that is termed Mox.
Macrophages exposed to oxidized phospholipids display reduced phagocytic and chemotactic abilities compared with M1- and M2-like
macrophages and are characterized by the expression of the transcription factor NFE2L2 as far as Hmox1, Srxn1, Txnrd1, and Gsr genes.
Mox macrophages also activate TLR2dependent mechanisms in response to oxidized lipids leading to an increase of IL1β and COX-2 (B).
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the enzyme that re-esteriﬁcates free cholesterol in cholesteryl
fatty acid esters [198]. Seimon et al. showed that oxidized
phospholipids, oxidized LDL, saturated fatty acids (SFAs),
and lipoprotein(a) can induce apoptosis in ER-stressed mac-
rophages through a CD36- and TLR2-dependent mechanism
[201] (Figure 4).
Several in vivo studies have demonstrated macrophage
heterogeneity within the atherosclerotic plaque in response
to the exposition of lipids and their oxidized derivatives
[202]. Indeed, within atherosclerotic microenvironment,
macrophages adapt their phenotype activating speciﬁc tran-
scriptional programs. Cholesterol crystals that accumulate
during the early stages of the atherosclerotic process might
be involved in the activation of macrophages [202]. Choles-
terol crystals can promote the caspase1-activating NLRP3
inﬂammasome, which results in the cleavage and secretion
of IL-1 and may act as a M1-polarizing stimulus [203]. The
proinﬂammatory M1-like phenotype can also be promoted
by a mechanism that involves inhibition of the transcription
Kruppel-like factor 2 [204, 205] or the activation of the
TLR4-mediated pathway that in turn leads to the activation
of NFκB [206]. Conversely, the anti-inﬂammatory M2-like
phenotype is induced by 9-oxononanoyl cholesterol, a major
cholesteryl ester oxidation product that can enhance TGFβ
secretion [207]. Moreover, sphingolipid metabolites, such
sphingosine1phosphate (S1P), promote the switching pheno-
type of mouse macrophages from M1- to M2-like state, by
activating S1P1 receptor [208].
Recently, a third macrophage phenotype has been
described in the atherosclerosis context that has been termed
Mox (Figure 4) and represents macrophages exposed to oxi-
dized phospholipids [209–211]. In advanced atherosclerotic
lesions of mice, Mox macrophages comprise approximately
30% of the total number of macrophages [212]. Mox pheno-
type can be triggered by the activation of transcription factor
NFE2L2 [212, 213]. Mox macrophages display reduced
phagocytic and chemotactic abilities compared with M1-
and M2-like macrophages. In mice, Mox macrophages typi-
cally express NFE2L2-mediated redox regulatory genes,
including Hmox1, Srxn1, Txnrd1, and Gsr [212]. Neverthe-
less, in response to oxidized phospholipids, Mox macro-
phages activate TLR2-dependent mechanisms that lead to
an increase of IL-1β and COX-2 expression [214].
Circulatingmonocytes inmurinemodels have been classi-
ﬁed into two major subsets, described as Ly6Chi and Ly6Clow
monocytes. In apolipoprotein E-deﬁcient (ApoE−/−), mice
the increase of Ly6Chi subset (corresponding to human
M1-like subset) has been observed within atherosclerotic
plaques [215].
Several studies have also correlated macrophage polar-
ization with the clinical course of atherosclerosis. Among
all, de Gaetano et al. [216] observed a marked diﬀerence
in a macrophage subset between symptomatic and asymp-
tomatic plaques. Indeed, M1 macrophages were found to
be abundant in the developed lipid core of the symptom-
atic plaque and were rarely found in the intimal regions
of the plaque, while M2-like macrophage number was
higher in asymptomatic atherosclerotic plaques, suggesting
a potential protective role of M2-like macrophages.
Moreover, in mouse models, it has been demonstrated that
in the regressing plaque a decrease in the number of mac-
rophages occurs and, in some, a switch of their phenotypic
characteristics has been observed, with an enrichment in
M2-like phenotype, suggesting that this is a common sig-
nature of regressing plaques [217].
Despite several current standard therapies for athero-
sclerosis that may inﬂuence general immune responses,
including angiotensin-converting enzyme (ACE) inhibitors,
β-blockers, aspirin, and corticosteroids, these drugs lack
speciﬁc macrophage targeting and may only be recognized
as mild modiﬁers of macrophage activity [218]. Several com-
mon pharmacological agents have already been proposed to
modulate macrophage activity for the prevention as well as
the treatment of inﬂammatory-related diseases, including
atherosclerosis. PPAR-γ is a crucial factor involved in the
regulation of macrophage lipid metabolism and inﬂamma-
tory responses and, as already discussed above, is upregulated
in M2-like macrophages [25]. PPAR-γ activators might have
therapeutic potential, and studies conducted by Bai et al.
[219] suggest that mediator 1 (MED1) is required for the
PPAR-γ-induced M2 phenotype switch and showed that
MED1 in macrophages has an antiatherosclerotic activity
via PPAR-γ-regulated transactivation, suggesting MED1 as
a promising target for atherosclerosis therapy.
Natural ligands such prostaglandins and some pharma-
cological agents including anti-TZD that have been demon-
strated to activate PPAR-γ have also been shown to
decrease atherosclerosis progression. Choi et al. demon-
strated that 5-(4-hydroxy-2,3,5-trimethylbenzylidene) thia-
zolidine-2,4-dione (HMB-TZD) reduced leukotriene B4
(LTB4) production and cytokine production by RAW264.7
macrophages and attenuates atherosclerosis possibly by
reducing monocyte recruitment to the lesion [220]. In
in vivo studies, selective inactivation of macrophage PPAR-
γ impairs M2-like activation exacerbating diet-induced obe-
sity [154], suggesting that PPAR-γ inducer might have a
therapeutic potential. Likewise, liver X receptors (LXRs) have
been found to be upregulated in M2-like macrophages and
exert atheroprotective eﬀects by modulating cholesterol
metabolism and M1 macrophage-induced inﬂammatory
genes, including iNOS, COX-2, and IL-6 [221] (Figure 4).
Tangirala et al. have observed that in experimental models
of atherosclerosis, LXR agonists induced a reduction of pre-
existing plaque size and this was associated with LXR macro-
phage activity. Indeed, macrophage-speciﬁc loss of LXRs
resulted in a statistically signiﬁcant increase in lesion size
[222]. Moreover, the immunomodulatory drug ﬁngolimod
(FTY720) that has been described as a S1P1 receptor mod-
ulator has been shown to increase the proportion of M2-like
macrophages in atherosclerotic lesions and reduce lesion
progression in mice [223]. Statins, eﬀective cholesterol-
lowering agents, have also been reported to dampen immune
responses through inhibition of macrophage inﬂammatory
activity by increasing eﬀerocytosis in vitro in a 3-hydroxyl-
3-methylglutaryl coenzyme A (HMG-CoA) reductase-
dependent manner, decreasing membrane localization of
RhoA and preventing impaired eﬀerocytosis by lysophospha-
tidic acid, a potent inducer of RhoA [224].
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Stimulation of the macrophage autophagy-lysosomal sys-
tem by the natural sugar trehalose has been reported to reduce
the formation of the atherosclerotic plaque by limitingmacro-
phage apoptosis and necrosis in the plaque cores [225].
Finally, some Lactobacillus has been observed to regu-
late M1/M2-like macrophage ratio by suppressing ox-LDL
phagocytosis, thus blocking foam cell formation [226].
These data supported the employment of prebiotic or pro-
biotic in atherosclerosis.
5. Macrophages in Periodontitis: Killers
or Builders?
Gingivitis and periodontitis are two common diseases aﬀect-
ing the oral tissues and the health of the supporting struc-
tures of a tooth that share inﬂammation as a common
feature. While in gingivitis the inﬂammatory process is lim-
ited to the soft tissues, epithelium, and connective tissue, in
periodontitis, the inﬂammation is extended to the supporting
tissues, including the alveolar bone [227].
Chronic periodontitis (CPD) occurs in response to spe-
ciﬁc bacteria within the oral bioﬁlm and involves the destruc-
tion of tooth-supporting tissues. Major features for CPD are
accumulation of immune cells in gingival connective tissue,
resorption of alveolar bone, and the degradation of periodon-
tal connective tissues, which lead to increased tooth mobility
and eventual tooth loss [228, 229].
Chronic periodontitis is strongly associated with the
presence of Gram-negative anaerobic bacteria in subgingival
plaque, in particular, Porphyromonas gingivalis, Tannerella
forsythia, and Treponema denticola. Although initiated by
bacteria, the bone pathology in CPD is mediated almost
entirely by the host response that is thought to be responsible
for the local tissue destruction observed in periodontitis
[230]. In addition, the response to oral pathogens has sys-
temic consequences. For example, infection and chronic
inﬂammatory conditions, such as periodontitis, may inﬂu-
ence the atherogenic process [231, 232].
It has been reported that monocyte/macrophages act as
relevant killers in periodontal diseases by contributing to tis-
sue breakdown. Elevated numbers of macrophages/mono-
cytes associated with greater collagen breakdown and
higher level of MMPs have been observed in samples from
periodontitis [233]. Studies have shown that IL-1 was
expressed predominantly by macrophages in the tissue iso-
lated from periodontal patients [234]. In addition, higher
levels of Receptor activator of nuclear factor kappa-B ligand
(RANKL) protein, associated with macrophages, have been
observed in the periodontitis tissues [235].
Activated macrophages have been found in the gingival
epithelium, lamina propria, and perivascular tissues and in
the blood vessels in human CPD. As lesions are associated
with chronic periodontitis progress, increasing numbers of
macrophages inﬁltrate into the gingival tissues [236]. There-
fore, the gingival tissue and crevicular ﬂuid of patients with
chronic periodontitis have been reported to contain signiﬁ-
cantly increased amounts of CCL3, also known as macro-
phage inﬂammatory protein- (MIP-) 1α and CXCL-8/IL-8,
as compared to healthy subjects [237, 238].
Porphyromonas gingivalis (Pg) is a key periodontal path-
ogen that promotes dysbiosis between host-and plaque-
associated bacteria, thus resulting in both periodontal disease
onset and progression [239, 240]. LPS from Pg activates mac-
rophages through both TLR2 and TRL4 [241], and speciﬁ-
cally, TLR2 activation by Pg LPS triggers the downstream
stimulation of NF-κB, leading to the production of proin-
ﬂammatory cytokines [242–244] (Figure 5).
Macrophages are frequently used as the in vitro model
cells to deﬁne immune cell function in CPD studies. Transfer
of TLR2 expressing macrophages to TLR2-deﬁcient mice
restored host sensitivity to Pg oral challenge [245] (Figure 5).
Pg LPS, in the presence of IL-1 and TNF-α, has been
shown to induce cultured human ﬁbroblasts and epithelial
cells to release PGE2, a factor associated with periodontal
bone resorption that promotes the proinﬂammatory M1-
like macrophage polarization [229, 246–250] (Figure 5).
IL-1 and TNF-α not only enhance inﬂammation but also
promote bone resorption, a major concern in periodontitis
[251–253]. Oral infection with Pg in BALB/c and C57BL/6
mice resulted in the inﬂux of M1 macrophages into the
submandibular lymph node (SMLN) and gingival tissue,
together with an increase in alveolar bone resorption, as
compared with untreated mice in a murine model of peri-
odontitis [254, 255]. Selective SMLN macrophage in vivo
depletion, using liposomes containing the proapoptotic
agent clodronate, resulted in decreased Pg-induced alveolar
bone in vivo resorption.
Pg infection enhances the secretion of the cytokines IL-
1β, IL-6, IL-12, TNF-α, CSF-3 (G-CSF), and CSF-2 (GM-
CSF), in addition to the chemokines eotaxin and CCL2–4
from macrophages, reﬂecting a M1 proinﬂammatory
response (Figure 5). These cytokines and chemokines are
known to act as proinﬂammatory mediators, to induce
monocytes to migrate from the bloodstream into the gingival
tissue, and to act synergistically to further stimulate proin-
ﬂammatory cytokine production [246, 248, 249, 256]. IL-
10, which is mainly produced by macrophages, was detected
among the wide array of cytokines released during Pg infec-
tion [257]. IL-10 strongly supports M2-like macrophage
and polarized functions including increased production of
arginase-1, higher collagen deposition, and induction of
ﬁbrosis in gingival tissue, all common clinical features of
chronic periodontitis [258–260].
In a recent study, Lam et al. observed that Pg can persist
in naïve and M2-like, but not M1-like, macrophages for 24
hours. Phagocytosis of Pg also induced high levels of TNF-
α, IL-12, and iNOS in M1 macrophages, but not in naïve
macrophages (MØ) or M2 macrophages [254].
T. forsythia expresses a well-characterized TLR2 ligand,
the BspA protein, and N- and O-glycan-linked glycoproteins
that comprise its surface- (S-) layer, covering the outer mem-
brane [261]. This S-layer has been shown to be important in
delaying the cytokine responses of monocyte and macro-
phage cells in vitro [262, 263]. BspA and other ligands
of T. forsythia induce TLR2 signaling favoring the devel-
opment of Th2-type inﬂammatory responses detrimental
to the alveolar bone that has been shown to be limited
in TLR2−/− mice [242].
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T. forsythia whole cells induced signiﬁcantly greater
amounts of IL-6 and IL-10 in wild-type (BALB/c) bone
marrow-derived dendritic cells (BM-DCs) and macrophages,
markers related to an M2-like polarization, as compared with
TLR2−/− cells. The macrophage-inducible C-type lectin recep-
tor (Mincle), a FcγR-coupled pathogen recognition receptor
(PRR) [263, 264], has been reported to contribute to
macrophage polarization [265]. THP-1 macrophages infected
with the puriﬁed S-layer on whole wild-type T. forsythia elicit
aM2-like polarization (IL-10, TNF-α) that is limited inMincle
knockdown macrophages or where infection is performed
with the S-layer TfΔtfsAB-mutated form [265] (Figure 5).
Treponema denticola is among the most frequently iso-
lated oral spirochetal species in patients with periodontitis
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Figure 5: Macrophage polarization in periodontitis. Macrophages that have been found in the gingival epithelium can be activated by several
microorganisms able to induce macrophage polarization toward M1- or M2-like phenotype. P. gingivalis releases LPS, IL-1, and TNF-α that
promote the proinﬂammatory M1 macrophage polarization (A). Moreover, Pg infection enhances the secretion of IL-1β, IL-6, IL-12, TNF-α,
G-CSF, GM-CSF, and the chemokines eotaxin, MCP1, MIP-1α, and MIP-1β from macrophages, reﬂecting a M1-like proinﬂammatory
response (B). In spite of this, it has also been reported that Pg infection can also be associated with the increase of IL10, supporting M2
macrophage and increasing arginase-1 production and collagen deposition, leading to periodontitis (C). T. forsythia releases BspA and
other ligands that induce TLR2 signaling favouring the development of Th2-type inﬂammatory responses (D). T. denticola induces TLR2
signaling that stimulates the prolonged activation of both ERK1/2 p38 and JNK1/2 in monocytes (E).
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[266, 267]. Major surface protein complex (MSPc), which is
expressed on the envelope of this treponema, plays a key role
in the interaction between T. denticola and gingival cells and
the related cytopathic eﬀects [268]. Treponema denticola
within the periodontium of the host has been reported to
be associated with localized inﬂammation. MSPc has been
showed to stimulate the release of the proinﬂammatory cyto-
kines NO, TNF-α, and IL-1β from murine macrophages,
both in LPS-responsive and LPS-nonresponsive murine mac-
rophages [269]. Furthermore, IL-1β, IL-6, and TNF-α secre-
tion by T. denticola-activated macrophages has been shown
to exhibit potent bone reabsorption eﬀects due to their proos-
teoclastic properties [270].
T. denticola-mediated macrophage response is mainly
mediated by TLR2 and via MAP kinases [271]. One of the
most highly conserved signaling cascades activated in both
the innate and the adaptive immune systems involves a fam-
ily of MAPKs including ERK1/2, p38, and JNK1/2 [272].
T. denticola stimulates the prolonged activation of both
ERK1/2 and p38 in monocytes, and pharmacological inhibi-
tion of these pathways plays major roles in regulating both
pro- and anti-inﬂammatory cytokine productions by T. den-
ticola-stimulated monocytes [271] (Figure 5).
A study from Miyajima et al. reported a correlation
between periodontitis-activated monocytes/macrophages
and aortic inﬂammation in an in vivo ligature-induced exper-
imental model of periodontitis. Gene expression proﬁling in
circulating monocytes in this experimental model showed
that periodontitis induced a M1-like speciﬁc signature with
high levels of TNF-α and IL-6 as compared to controls, indi-
cating that a M1-like phenotype of macrophages is induced
by periodontitis [273]. This in turn supports the hypothesis
that periodontitis-induced M1-like macrophages are the
inﬂammatory orchestrators driving speciﬁc proinﬂammatory
messages to the systemic vasculature [273]. The work from
Miyajima et al. also showed that periodontitis-induced M1
macrophages can increase macrophage adhesion to aortic
endothelial cells through the NF-κB/VCAM-1 axis [273].
These results clearly suggest that local-tissue alterations of
macrophages during periodontitis can impact on circulating
monocyte polarization and are associated to vascular alter-
ations involved in apparently distant pathologies that shares
inﬂammatory cell polarization as common features.
6. Conclusion
It is now widely accepted that inﬂammation represents a
host hallmark of diverse chronic diseases, ranging from
cancer, diabetes, and metabolic, cardiovascular, and neuro-
logical/neurodegenerative disorders. In the sameway, inﬂam-
mation has been recognized as a relevant condition for
insurgence, maintenance, and progression of such disorders.
Cell plasticity is a key and shared feature of inﬂammatory
cells within the host organism that can potentially acquire
killer (M1-like) or builder (M2-like) properties, based on
the surrounding environment. Macrophages are the clearest
example of immune cells that can be switched from killers
to builders and vice versa, and this has been observed in all
the inﬂammatory-based/associated disorders. Here we
discussed the cellular and molecular mechanisms involved
in macrophage switching to killers or builders in diﬀer-
ently and apparently distant disorders, pointing out the
attention on how the macrophages/microenvironment
reciprocal interaction shape their polarization and distinct
functional states.
Further, we discussed some approaches aimed at resolv-
ing this process, by interfering with aberrant macrophage
killer/builder reciprocal switch. With this knowledge, it is
clear that the identiﬁcation of novel preventive and interven-
tion strategies, along with eﬀective compounds able in
targeting/limiting/reverting proinﬂammatory macrophage
polarization, are urgently needed and may represent a rele-
vant tool to shape macrophage function action directly on
them or on the hosting/surrounding environment.
Abbreviations
ACAT: Acyl-CoA:cholesterol acyltransferase
ADM: Adrenomedullin
AKT: Protein kinase B
AMPK: Adenosine monophosphate kinase
ATMs: Adipose tissue macrophages
Bcl2: B-cell lymphoma 2
bFGF: Basic ﬁbroblast growth factor
BspA: Bark storage protein A
c-Maf: Avian musculoaponeurotic ﬁbrosarcoma
oncogene homolog
c-Myc: Avian myelocytomatosis viral oncogene
homolog
C/EBP: CCAAT-enhancer-binding proteins
CCR: Chemokine receptor
CD: Cluster of diﬀerentiation
COX: Cyclooxygenase
CPD: Chronic periodontitis
CSF-1: Colony-stimulating factor 1
CSF-1R: Colony-stimulating factor 1 receptor
CXCL: C-X-C chemokine ligand
CXCR: C-X-C chemokine receptor
DC-SIGN: Dendritic cell-speciﬁc ICAM-grabbing
nonintegrin
DC: Dendritic cells
DNAm: DNA methylation
DNMT: DNA methyltransferase
ECM: Extracellular matrix
ER: Endoplasmic reticulum
ERK: Extracellular signal-regulated kinase
G-CSF: Granulocyte colony-stimulating factor
GM-CSF: Granulocyte macrophage colony-stimulating
factor
GSR: Glutathione-disulﬁde reductase
HDAC: Histone deacetylase
HIF: Hypoxia-inducible factor
HMB-TZD: 5-(4-Hydroxy-2,3,5-trimethylbenzylidene)
thiazolidine-2,4-dione
HMG-CoA: 3-Hydroxyl-3-methylglutaryl coenzyme A
Hmox1: Heme oxygenase 1
IFN: Interferon
IKK: IκB kinase
15Journal of Immunology Research
IKKβ: Inhibitor of IKκB kinase
IL: Interleukin
iNOS: Inducible nitric oxide synthase
IRAK: Interleukin receptor-associated kinase
IRF: Interferon regulatory factor
JNK: Jun N-terminal kinase
KLF4: Kruppel-like factor 4
LDL: Low-density lipoprotein
let-7: Lethal-7
LPS: Lipopolysaccharide
LTB4: Leukotriene B4
LXRs: Liver X receptors
M-CSF: Macrophage colony-stimulating factor
M: Macrophage
MAPK: Mitogen-activated protein kinase
MCP: Monocyte chemoattractant protein
MCP1: Monocyte chemoattractant protein-1
MDSCs: Myeloid-derived suppressor cells
MED1: Mediator 1
MgI1: Macrophage and granulocyte inducer-form 1
MIF: Macrophage migration inhibitory factor
Mincle: Macrophage-inducible C-type lectin receptor
MIP: Macrophage inﬂammatory protein
miRNA/miR: Micro-RNA
MMPs: Metalloproteases
MØ: Naïve macrophages
Mox: Macrophages exposed to oxidized
phospholipids
MPS: Mononuclear phagocyte system
MSPc: Major surface protein complex
NF-κB: Nuclear factor kappa-light-chain-enhancer
of activated B-cells
NFE2L2: Nuclear factor- (erythroid-derived 2) like 2
NLRP3: NLR family pyrin domain containing 3
NO: Nitric oxide
NRP1: Neuropilin-1
ox-LDL: Oxidized LDL
PD: Periodontitis
Pg: Porphyromonas gingivalis
PGC-1α: Peroxisome proliferator-activated receptor
gamma coactivator 1-alpha
PGE2: Prostaglandin E2
Pknox1: PBX/knotted 1 homeobox 1
PPAR: Peroxisome proliferator-activated receptor
PRR: Pathogen recognition receptor
RANTES: Regulated on activation, normal T cell
expressed and secreted
S1P: Sphingosine1phosphate
SDF-1: Stromal cell-derived factor-1
Sema4D: Semaphorin 4D
SFAs: Saturated fatty acids
SIRPa: Signal-regulatory protein
SMAD: Small mother against decapentaplegic
SMLN: Submandibular lymph node
SOCS1: Suppressor of cytokine signaling 1
Srxn1: Sulﬁredoxin-1
STAT: Signal transducers and activators of
transcription
T2D: Type 2 diabetes
TAM: Tumour-associated macrophage
TEMs: Tie2-expressing monocytes
TGF: Transforming growth factor
Th: T helper
TLR: Toll-like receptor
TNF: Tumour necrosis factor
TP: Thymidine phosphorylase
TRAF: TNF receptor-associated factor
Txnrd1: Thioredoxin reductase 1
TZD: Thiazolidinediones
uPA: Urokinase-type plasminogen activator
VCAM: Vascular cell adhesion molecule
VEGF: Vascular endothelial growth factor
YM1: Chitinase 3-like 3.
Disclosure
Antonino Bruno was a FIRC (Fondazione Italiana per la
Ricerca sul Cancro) fellow and a fellow of Fondazione
Umberto Veronesi (FUV).
Conflicts of Interest
The authors declare that they have no competing interests.
Authors’ Contributions
Luca Parisi and Elisabetta Gini share equal contribution as
ﬁrst authors. Giampietro Farronato, Antonino Bruno, and
Lorenzo Mortara share equal contribution as last authors.
References
[1] F. Geissmann, M. G.Manz, S. Jung, M. H. Sieweke, M.Merad,
and K. Ley, “Development of monocytes, macrophages, and
dendritic cells,” Science, vol. 327, no. 5966, pp. 656–661, 2010.
[2] F. Ginhoux, M. Greter, M. Leboeuf et al., “Fate mapping anal-
ysis reveals that adult microglia derive from primitive macro-
phages,” Science, vol. 330, no. 6005, pp. 841–845, 2010.
[3] S. Gordon and P. R. Taylor, “Monocyte and macrophage
heterogeneity,” Nature Reviews Immunology, vol. 5, no. 12,
pp. 953–964, 2005.
[4] L. C. Davies, S. J. Jenkins, J. E. Allen, and P. R. Taylor, “Tis-
sue-resident macrophages,” Nature Immunology, vol. 14,
no. 10, pp. 986–995, 2013.
[5] A. Dey, J. Allen, and P. A. Hankey-Giblin, “Ontogeny and
polarization of macrophages in inﬂammation: blood mono-
cytes versus tissue macrophages,” Frontiers in Immunology,
vol. 5, p. 683, 2014.
[6] J. Sheng, C. Ruedl, and K. Karjalainen, “Most tissue-resident
macrophages except microglia are derived from fetal hemato-
poietic stem cells,” Immunity, vol. 43, no. 2, pp. 382–393,
2015.
[7] E. Gomez Perdiguero, K. Klapproth, C. Schulz et al., “Tissue-
resident macrophages originate from yolk-sac-derived
erythro-myeloid progenitors,” Nature, vol. 518, no. 7540,
pp. 547–551, 2015.
[8] S. Epelman, K. J. Lavine, A. E. Beaudin et al., “Embryonic and
adult-derived resident cardiac macrophages are maintained
through distinct mechanisms at steady state and during
inﬂammation,” Immunity, vol. 40, no. 1, pp. 91–104, 2014.
16 Journal of Immunology Research
[9] D. Hashimoto, A. Chow, C. Noizat et al., “Tissue-resident
macrophages self-maintain locally throughout adult life with
minimal contribution from circulating monocytes,” Immu-
nity, vol. 38, no. 4, pp. 792–804, 2013.
[10] M. Merad, M. G. Manz, H. Karsunky et al., “Langerhans cells
renew in the skin throughout life under steady-state condi-
tions,” Nature Immunology, vol. 3, no. 12, pp. 1135–1141,
2002.
[11] S. Yona, K. W. Kim, Y. Wolf et al., “Fate mapping reveals ori-
gins and dynamics of monocytes and tissue macrophages
under homeostasis,” Immunity, vol. 38, no. 1, pp. 79–91,
2013.
[12] D. K. Fogg, C. Sibon, C. Miled et al., “A clonogenic bone mar-
row progenitor speciﬁc for macrophages and dendritic cells,”
Science, vol. 311, no. 5757, pp. 83–87, 2006.
[13] K. Liu, G. D. Victora, T. A. Schwickert et al., “In vivo analysis
of dendritic cell development and homeostasis,” Science,
vol. 324, no. 5925, pp. 392–397, 2009.
[14] V. Garceau, J. Smith, I. R. Paton et al., “Pivotal advance: avian
colony-stimulating factor 1 (CSF-1), interleukin-34 (IL-34),
and CSF-1 receptor genes and gene products,” Journal of Leu-
kocyte Biology, vol. 87, no. 5, pp. 753–764, 2010.
[15] S. Bashir, Y. Sharma, A. Elahi, and F. Khan, “Macrophage
polarization: the link between inﬂammation and related dis-
eases,” Inﬂammation Research, vol. 65, no. 1, pp. 1–11, 2016.
[16] S. Romagnani, “Th1/Th2 cells,” Inﬂammatory Bowel Dis-
eases, vol. 5, no. 4, pp. 285–294, 1999.
[17] S. Romagnani, “T-cell subsets (Th1 versus Th2),” Annals of
Allergy, Asthma & Immunology, vol. 85, no. 1, pp. 9–18,
2000, 21.
[18] C. D. Mills, K. Kincaid, J. M. Alt, M. J. Heilman, and A. M.
Hill, “M-1/M-2 macrophages and the Th1/Th2 paradigm,”
The Journal of Immunology, vol. 164, no. 12, pp. 6166–6173,
2000.
[19] A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and
M. Locati, “The chemokine system in diverse forms of macro-
phage activation and polarization,” Trends in Immunology,
vol. 25, no. 12, pp. 677–686, 2004.
[20] P. J. Murray, J. E. Allen, S. K. Biswas et al., “Macrophage acti-
vation and polarization: nomenclature and experimental
guidelines,” Immunity, vol. 41, no. 1, pp. 14–20, 2014.
[21] S. Fujisaka, I. Usui, A. Bukhari et al., “Regulatory mechanisms
for adipose tissue M1 and M2 macrophages in diet-induced
obese mice,” Diabetes, vol. 58, no. 11, pp. 2574–2582, 2009.
[22] A. Sica and A. Mantovani, “Macrophage plasticity and polar-
ization: in vivo veritas,” The Journal of Clinical Investigation,
vol. 122, no. 3, pp. 787–795, 2012.
[23] F. O. Martinez, L. Helming, and S. Gordon, “Alternative acti-
vation of macrophages: an immunologic functional perspec-
tive,” Annual Review of Immunology, vol. 27, no. 1,
pp. 451–483, 2009.
[24] S. Galvan-Pena and L. A. O'Neill, “Metabolic reprograming
in macrophage polarization,” Frontiers in Immunology,
vol. 5, p. 420, 2014.
[25] M. A. Bouhlel, B. Derudas, E. Rigamonti et al., “PPARγ acti-
vation primes human monocytes into alternative M2 macro-
phages with anti-inﬂammatory properties,” Cell Metabolism,
vol. 6, no. 2, pp. 137–143, 2007.
[26] J. W. Graﬀ, A. M. Dickson, G. Clay, A. P. McCaﬀrey, and
M. E. Wilson, “Identifying functional microRNAs in
macrophages with polarized phenotypes,” The Journal of Bio-
logical Chemistry, vol. 287, no. 26, pp. 21816–21825, 2012.
[27] X. Cai, Y. Yin, N. Li et al., “Re-polarization of tumor-
associated macrophages to pro-inﬂammatory M1 macro-
phages by microRNA-155,” Journal of Molecular Cell Biology,
vol. 4, no. 5, pp. 341–343, 2012.
[28] R. T. Martinez-Nunez, F. Louaﬁ, and T. Sanchez-Elsner,
“The interleukin 13 (IL-13) pathway in human macro-
phages is modulated by microRNA-155 via direct targeting
of interleukin 13 receptor α1 (IL13Rα1),” The Journal of
Biological Chemistry, vol. 286, no. 3, pp. 1786–1794, 2011.
[29] V. Litvak, S. A. Ramsey, A. G. Rust et al., “Function of C/
EBPδ in a regulatory circuit that discriminates between tran-
sient and persistent TLR4-induced signals,” Nature Immu-
nology, vol. 10, no. 4, pp. 437–443, 2009.
[30] Y. C. Lu, I. Kim, E. Lye et al., “Diﬀerential role for c-Rel and
C/EBPβ/δ in TLR-mediated induction of proinﬂammatory
cytokines,” The Journal of Immunology, vol. 182, no. 11,
pp. 7212–7221, 2009.
[31] N. Wang, H. Liang, and K. Zen, “Molecular mechanisms that
inﬂuence the macrophage M1-M2 polarization balance,”
Frontiers in Immunology, vol. 5, p. 614, 2014.
[32] O. Takeuch and S. Akira, “Epigenetic control of macrophage
polarization,” European Journal of Immunology, vol. 41,
no. 9, pp. 2490–2493, 2011.
[33] D. Zhou, K. Yang, L. Chen et al., “Promising landscape for
regulating macrophage polarization: epigenetic viewpoint,”
Oncotarget, vol. 8, no. 34, pp. 57693–57706, 2017.
[34] M. A. Hoeksema and M. P. J. de Winther, “Epigenetic regula-
tion of monocyte and macrophage function,” Antioxidants &
Redox Signaling, vol. 25, no. 14, pp. 758–774, 2016.
[35] A. Ambade, A. Satishchandran, B. Saha et al., “Hepatocellular
carcinoma is accelerated by NASH involvingM2macrophage
polarization mediated by hif-1αinduced IL-10,” OncoImmu-
nology, vol. 5, no. 10, article e1221557, 2016.
[36] G. Lund, L. Andersson, M. Lauria et al., “DNA methyla-
tion polymorphisms precede any histological sign of ath-
erosclerosis in mice lacking apolipoprotein E,” The Journal
of Biological Chemistry, vol. 279, no. 28, pp. 29147–29154,
2004.
[37] J. Thangavel, S. Samanta, S. Rajasingh et al., “Epigenetic mod-
iﬁers reduce inﬂammation and modulate macrophage phe-
notype during endotoxemia-induced acute lung injury,”
Journal of Cell Science, vol. 128, no. 16, pp. 3094–3105,
2015.
[38] X. Wang, Q. Cao, L. Yu, H. Shi, B. Xue, and H. Shi, “Epige-
netic regulation of macrophage polarization and inﬂamma-
tion by DNA methylation in obesity,” JCI Insight, vol. 1,
no. 19, article e87748, 2016.
[39] A. C. MacKinnon, S. L. Farnworth, P. S. Hodkinson et al.,
“Regulation of alternative macrophage activation by galectin-
3,” The Journal of Immunology, vol. 180, no. 4, pp. 2650–
2658, 2008.
[40] J. Y. Lee, N. A. Kim, A. Sanford, and K. E. Sullivan, “Histone
acetylation and chromatin conformation are regulated sepa-
rately at the TNF-α promoter in monocytes and macro-
phages,” Journal of Leukocyte Biology, vol. 73, no. 6,
pp. 862–871, 2003.
[41] S. Garrett, K. Dietzmann-Maurer, L. Song, and K. E. Sullivan,
“Polarization of primary humanmonocytes by IFN-γ induces
chromatin changes and recruits RNA pol II to the TNF-α
17Journal of Immunology Research
promoter,” The Journal of Immunology, vol. 180, no. 8,
pp. 5257–5266, 2008.
[42] M. R. Shakespear, M. A. Halili, K. M. Irvine, D. P. Fairlie, and
M. J. Sweet, “Histone deacetylases as regulators of inﬂamma-
tion and immunity,” Trends in Immunology, vol. 32, no. 7,
pp. 335–343, 2011.
[43] P. J. Barnes, I. M. Adcock, and K. Ito, “Histone acetylation
and deacetylation: importance in inﬂammatory lung dis-
eases,” European Respiratory Journal, vol. 25, no. 3,
pp. 552–563, 2005.
[44] X. Chen, I. Barozzi, A. Termanini et al., “Requirement for the
histone deacetylase Hdac3 for the inﬂammatory gene expres-
sion program in macrophages,” Proceedings of the National
Academy of Sciences of the United States of America,
vol. 109, no. 42, pp. E2865–E2874, 2012.
[45] S. E. Mullican, C. A. Gaddis, T. Alenghat et al., “Histone dea-
cetylase 3 is an epigenomic brake in macrophage alternative
activation,” Genes & Development, vol. 25, no. 23, pp. 2480–
2488, 2011.
[46] A. Bruno, A. Pagani, E. Magnani et al., “Inﬂammatory angio-
genesis and the tumor microenvironment as targets for
cancer therapy and prevention,” Cancer Treatment and
Research, vol. 159, pp. 401–426, 2014.
[47] A. Bruno, A. Pagani, L. Pulze et al., “Orchestration of angio-
genesis by immune cells,” Frontiers in Oncology, vol. 4, p. 131,
2014.
[48] D. M. Noonan, A. de Lerma Barbaro, N. Vannini, L. Mortara,
and A. Albini, “Inﬂammation, inﬂammatory cells and angio-
genesis: decisions and indecisions,” Cancer and Metastasis
Reviews, vol. 27, no. 1, pp. 31–40, 2008.
[49] T. J. Koh and L. A. DiPietro, “Inﬂammation and wound heal-
ing: the role of the macrophage,” Expert Reviews in Molecular
Medicine, vol. 13, article e23, 2011.
[50] M. L. Novak and T. J. Koh, “Phenotypic transitions of macro-
phages orchestrate tissue repair,” The American Journal of
Pathology, vol. 183, no. 5, pp. 1352–1363, 2013.
[51] H. W. Zimmermann, C. Trautwein, and F. Tacke, “Func-
tional role of monocytes and macrophages for the inﬂamma-
tory response in acute liver injury,” Frontiers in Physiology,
vol. 3, p. 56, 2012.
[52] S. R. Nielsen and M. C. Schmid, “Macrophages as key drivers
of cancer progression and metastasis,” Mediators of Inﬂam-
mation, vol. 2017, Article ID 9624760, 11 pages, 2017.
[53] R. Noy and J. W. Pollard, “Tumor-associated macrophages:
from mechanisms to therapy,” Immunity, vol. 41, no. 1,
pp. 49–61, 2014.
[54] M. D. Vesely, M. H. Kershaw, R. D. Schreiber, and M. J.
Smyth, “Natural innate and adaptive immunity to cancer,”
Annual Review of Immunology, vol. 29, no. 1, pp. 235–271,
2011.
[55] D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the
next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
[56] A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-
related inﬂammation,” Nature, vol. 454, no. 7203, pp. 436–
444, 2008.
[57] B. Ruﬀell and L. M. Coussens, “Macrophages and therapeu-
tic resistance in cancer,” Cancer Cell, vol. 27, no. 4, pp. 462–
472, 2015.
[58] V. Kumar, P. Cheng, T. Condamine et al., “CD45 phospha-
tase inhibits STAT3 transcription factor activity in myeloid
cells and promotes tumor-associated macrophage diﬀerentia-
tion,” Immunity, vol. 44, no. 2, pp. 303–315, 2016.
[59] M. Groblewska, B. Mroczko, U. Wereszczyńska-Siemiat-
kowska, P. Myśliwiec, B. Kedra, and M. Szmitkowski, “Serum
levels of granulocyte colony-stimulating factor (G-CSF) and
macrophage colony-stimulating factor (M-CSF) in pancre-
atic cancer patients,” Clinical Chemistry and Laboratory
Medicine, vol. 45, no. 1, pp. 30–34, 2007.
[60] S. Huang, K. Xie, C. D. Bucana, S. E. Ullrich, and M. Bar-Eli,
“Interleukin 10 suppresses tumor growth and metastasis of
human melanoma cells: potential inhibition of angiogenesis,”
Clinical Cancer Research, vol. 2, no. 12, pp. 1969–1979, 1996.
[61] C. Lan, X. Huang, S. Lin et al., “Expression of M2-polarized
macrophages is associated with poor prognosis for advanced
epithelial ovarian cancer,” Technology in Cancer Research &
Treatment, vol. 12, no. 3, pp. 259–267, 2013.
[62] B. Z. Qian and J. W. Pollard, “Macrophage diversity enhances
tumor progression and metastasis,” Cell, vol. 141, no. 1,
pp. 39–51, 2010.
[63] M. Ryder, R. A. Ghossein, J. C. M. Ricarte-Filho, J. A. Knauf,
and J. A. Fagin, “Increased density of tumor-associated mac-
rophages is associated with decreased survival in advanced
thyroid cancer,” Endocrine-Related Cancer, vol. 15, no. 4,
pp. 1069–1074, 2008.
[64] C. Steidl, T. Lee, S. P. Shah et al., “Tumor-associated macro-
phages and survival in classic Hodgkin’s lymphoma,” The
New England Journal of Medicine, vol. 362, no. 10, pp. 875–
885, 2010.
[65] J. Xu, J. Escamilla, S. Mok et al., “CSF1R signaling blockade
stanches tumor-inﬁltrating myeloid cells and improves the
eﬃcacy of radiotherapy in prostate cancer,” Cancer Research,
vol. 73, no. 9, pp. 2782–2794, 2013.
[66] J. Forssell, A. Oberg, M. L. Henriksson, R. Stenling, A. Jung,
and R. Palmqvist, “High macrophage inﬁltration along the
tumor front correlates with improved survival in colon can-
cer,” Clinical Cancer Research, vol. 13, no. 5, pp. 1472–1479,
2007.
[67] S. J. Kim, J. S. Kim, J. Papadopoulos et al., “Circulating mono-
cytes expressing CD31: implications for acute and chronic
angiogenesis,” The American Journal of Pathology, vol. 174,
no. 5, pp. 1972–1980, 2009.
[68] S. E. Shoelson, J. Lee, and A. B. Goldﬁne, “Inﬂammation and
insulin resistance,” The Journal of Clinical Investigaton,
vol. 116, no. 7, pp. 1793–1801, 2006.
[69] T. J. Welsh, R. H. Green, D. Richardson, D. A. Waller, K. J.
O'Byrne, and P. Bradding, “Macrophage and mast-cell inva-
sion of tumor cell islets confers a marked survival advantage
in non-small-cell lung cancer,” Journal of Clinical Oncology,
vol. 23, no. 35, pp. 8959–8967, 2005.
[70] E. S. White, K. R. Flaherty, S. Carskadon et al., “Macrophage
migration inhibitory factor and CXC chemokine expression
in non-small cell lung cancer: role in angiogenesis and prog-
nosis,” Clinical Cancer Research, vol. 9, no. 2, pp. 853–860,
2003.
[71] J. W. Pollard, “Trophic macrophages in development and
disease,” Nature Reviews Immunology, vol. 9, no. 4,
pp. 259–270, 2009.
[72] H. Yang, C. Kim, M. J. Kim et al., “Soluble vascular endothe-
lial growth factor receptor-3 suppresses lymphangiogenesis
and lymphatic metastasis in bladder cancer,” Molecular
Cancer, vol. 10, no. 1, p. 36, 2011.
18 Journal of Immunology Research
[73] A. L. Mescher, “Macrophages and ﬁbroblasts during inﬂam-
mation and tissue repair in models of organ regeneration,”
Regeneration, vol. 4, no. 2, pp. 39–53, 2017.
[74] A. Mukwaya, B. Peebo, M. Xeroudaki et al., “Factors regulat-
ing capillary remodeling in a reversible model of inﬂamma-
tory corneal angiogenesis,” Scientiﬁc Reports, vol. 6, no. 1,
article 32137, 2016.
[75] M. E. Ogle, C. E. Segar, S. Sridhar, and E. A. Botchwey,
“Monocytes and macrophages in tissue repair: implications
for immunoregenerative biomaterial design,” Experimental
Biology and Medicine, vol. 241, no. 10, pp. 1084–1097, 2016.
[76] K. M. Vannella and T. A. Wynn, “Mechanisms of organ
injury and repair by macrophages,” Annual Review of Physi-
ology, vol. 79, no. 1, pp. 593–617, 2017.
[77] T. A. Wynn and K. M. Vannella, “Macrophages in tissue
repair, regeneration, and ﬁbrosis,” Immunity, vol. 44, no. 3,
pp. 450–462, 2016.
[78] C. Yang, L. He, P. He et al., “Increased drug resistance in
breast cancer by tumor-associated macrophages through IL-
10/STAT3/bcl-2 signaling pathway,” Medical Oncology,
vol. 32, no. 2, p. 352, 2015.
[79] F. T. Chung, K. Y. Lee, C. W. Wang et al., “Tumor-associated
macrophages correlate with response to epidermal growth
factor receptor-tyrosine kinase inhibitors in advanced non-
small cell lung cancer,” International Journal of Cancer,
vol. 131, no. 3, pp. E227–E235, 2012.
[80] A. Nowicki, J. Szenajch, G. Ostrowska et al., “Impaired tumor
growth in colony-stimulating factor 1 (CSF-1)-deﬁcient,
macrophage-deﬁcient op/op mouse: evidence for a role of
CSF-1-dependent macrophages in formation of tumor
stroma,” International Journal of Cancer, vol. 65, no. 1,
pp. 112–119, 1996.
[81] B. Ruﬀell, N. I. Aﬀara, and L. M. Coussens, “Diﬀerential mac-
rophage programming in the tumor microenvironment,”
Trends in Immunology, vol. 33, no. 3, pp. 119–126, 2012.
[82] D. J. Ceradini, A. R. Kulkarni, M. J. Callaghan et al., “Progen-
itor cell traﬃcking is regulated by hypoxic gradients through
HIF-1 induction of SDF-1,” Nature Medicine, vol. 10, no. 8,
pp. 858–864, 2004.
[83] J. W. Pollard, “Tumour-educated macrophages promote
tumour progression and metastasis,” Nature Reviews Cancer,
vol. 4, no. 1, pp. 71–78, 2004.
[84] S. Sousa and J. Maatta, “The role of tumour-associated mac-
rophages in bone metastasis,” Journal of Bone Oncology,
vol. 5, no. 3, pp. 135–138, 2016.
[85] Y. Nagakawa, T. Aoki, K. Kasuya, A. Tsuchida, and
Y. Koyanagi, “Histologic features of venous invasion, expres-
sion of vascular endothelial growth factor and matrix
metalloproteinase-2 and matrix metalloproteinase-9, and
the relation with liver metastasis in pancreatic cancer,” Pan-
creas, vol. 24, no. 2, pp. 169–178, 2002.
[86] D. F. Quail and J. A. Joyce, “Microenvironmental regulation
of tumor progression and metastasis,” Nature Medicine,
vol. 19, no. 11, pp. 1423–1437, 2013.
[87] S. Sangaletti, E. di Carlo, S. Gariboldi et al., “Macrophage-
derived SPARC bridges tumor cell-extracellular matrix inter-
actions toward metastasis,” Cancer Research, vol. 68, no. 21,
pp. 9050–9059, 2008.
[88] R. Hildenbrand, I. Dilger, A. Hörlin, and H. J. Stutte, “Uroki-
nase and macrophages in tumour angiogenesis,” British Jour-
nal of Cancer, vol. 72, no. 4, pp. 818–823, 1995.
[89] R. D. Leek, R. Landers, S. B. Fox, F. Ng, A. L. Harris, and C. E.
Lewis, “Association of tumour necrosis factor alpha and its
receptors with thymidine phosphorylase expression in inva-
sive breast carcinoma,” British Journal of Cancer, vol. 77,
no. 12, pp. 2246–2251, 1998.
[90] A. Mantovani, F. Marchesi, C. Porta, A. Sica, and P. Allavena,
“Inﬂammation and cancer: breast cancer as a prototype,”
Breast, vol. 16, Supplement 2, pp. S27–S33, 2007.
[91] J. R. Sierra, S. Corso, L. Caione et al., “Tumor angiogenesis
and progression are enhanced by Sema4D produced by
tumor-associated macrophages,” The Journal of Experimental
Medicine, vol. 205, no. 7, pp. 1673–1685, 2008.
[92] V. Riabov, A. Gudima, N. Wang, A. Mickley, A. Orekhov,
and J. Kzhyshkowska, “Role of tumor associated macro-
phages in tumor angiogenesis and lymphangiogenesis,” Fron-
tiers in Physiology, vol. 5, p. 75, 2014.
[93] A. Casazza, D. Laoui, M. Wenes et al., “Impeding macro-
phage entry into hypoxic tumor areas by Sema3A/Nrp1
signaling blockade inhibits angiogenesis and restores anti-
tumor immunity,” Cancer Cell, vol. 24, no. 6, pp. 695–
709, 2013.
[94] S. Ran and K. E. Montgomery, “Macrophage-mediated
lymphangiogenesis: the emerging role of macrophages as
lymphatic endothelial progenitors,” Cancer, vol. 4, no. 3,
pp. 618–657, 2012.
[95] S. B. Coﬀelt, R. Hughes, and C. E. Lewis, “Tumor-associated
macrophages: eﬀectors of angiogenesis and tumor progres-
sion,” Biochimica et Biophysica Acta (BBA) - Reviews on Can-
cer, vol. 1796, no. 1, pp. 11–18, 2009.
[96] F. G. Gomes, F. Nedel, A. M. Alves, J. E. Nör, and S. B. C.
Tarquinio, “Tumor angiogenesis and lymphangiogenesis:
tumor/endothelial crosstalk and cellular/microenvironmen-
tal signaling mechanisms,” Life Science, vol. 92, no. 2,
pp. 101–107, 2013.
[97] C. Scavelli, A. Vacca, G. di Pietro, F. Dammacco, and
D. Ribatti, “Crosstalk between angiogenesis and lymphangio-
genesis in tumor progression,” Leukemia, vol. 18, no. 6,
pp. 1054–1058, 2004.
[98] M. De Palma and L. Naldini, “Tie2-expressing monocytes
(TEMs): novel targets and vehicles of anticancer therapy?,”
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer,
vol. 1796, no. 1, pp. 5–10, 2009.
[99] C. E. Lewis, A. S. Harney, and J. W. Pollard, “The multiface-
ted role of perivascular macrophages in tumors,” Cancer Cell,
vol. 30, no. 1, pp. 18–25, 2016.
[100] R. Mazzieri, F. Pucci, D. Moi et al., “Targeting the ANG2/
TIE2 axis inhibits tumor growth and metastasis by impair-
ing angiogenesis and disabling rebounds of proangiogenic
myeloid cells,” Cancer Cell, vol. 19, no. 4, pp. 512–526,
2011.
[101] X. Wang, Q. Zhu, Y. Lin et al., “Crosstalk between TEMs
and endothelial cells modulates angiogenesis and metasta-
sis via IGF1-IGF1R signalling in epithelial ovarian cancer,”
British Journal of Cancer, vol. 117, no. 9, pp. 1371–1382,
2017.
[102] T. Chanmee, P. Ontong, K. Konno, and N. Itano,
“Tumor-associated macrophages as major players in the
tumor microenvironment,” Cancer, vol. 6, no. 3, pp. 1670–
1690, 2014.
[103] L.Mortara, A. V. Benest, D.O. Bates, andD.M.Noonan, “Can
the co-dependence of the immune system and angiogenesis
19Journal of Immunology Research
facilitate pharmacological targeting of tumours?,” Current
Opinion in Pharmacology, vol. 35, pp. 66–74, 2017.
[104] T. Kitamura, B. Z. Qian, and J. W. Pollard, “Immune cell pro-
motion of metastasis,” Nature Reviews Immunology, vol. 15,
no. 2, pp. 73–86, 2015.
[105] A. Sica, M. Erreni, P. Allavena, and C. Porta, “Macrophage
polarization in pathology,” Cellular and Molecular Life Sci-
ences, vol. 72, no. 21, pp. 4111–4126, 2015.
[106] S. Lenz and S. Lindenberg, “Is the corpus luteum normal after
ovulation induction?,” Journal of Clinical Ultrasound, vol. 18,
no. 3, pp. 155–159, 1990.
[107] J. Liu, N. Zhang, Q. Li et al., “Tumor-associated macrophages
recruit CCR6+ regulatory T cells and promote the develop-
ment of colorectal cancer via enhancing CCL20 production
in mice,” PLoS One, vol. 6, no. 4, article e19495, 2011.
[108] T. J. Curiel, G. Coukos, L. Zou et al., “Speciﬁc recruitment of
regulatory T cells in ovarian carcinoma fosters immune priv-
ilege and predicts reduced survival,”Nature Medicine, vol. 10,
no. 9, pp. 942–9, 2004.
[109] S. K. Biswas and A. Mantovani, “Macrophage plasticity and
interaction with lymphocyte subsets: cancer as a paradigm,”
Nature Immunology, vol. 11, no. 10, pp. 889–896, 2010.
[110] A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica,
“Macrophage polarization: tumor-associated macrophages as
a paradigm for polarized M2 mononuclear phagocytes,”
Trends in Immunology, vol. 23, no. 11, pp. 549–555, 2002.
[111] I. Marigo, L. Dolcetti, P. Seraﬁni, P. Zanovello, and V. Bronte,
“Tumor-induced tolerance and immune suppression by mye-
loid derived suppressor cells,” Immunological Reviews,
vol. 222, no. 1, pp. 162–179, 2008.
[112] B. Costa-Silva, N.M. Aiello, A. J. Ocean et al., “Pancreatic can-
cer exosomes initiate pre-metastatic niche formation in the
liver,” Nature Cell Biology, vol. 17, no. 6, pp. 816–826, 2015.
[113] A. M. Gil-Bernabe, S. Ferjancic, M. Tlalka et al., “Recruitment
of monocytes/macrophages by tissue factor-mediated coagu-
lation is essential for metastatic cell survival and premeta-
static niche establishment in mice,” Blood, vol. 119, no. 13,
pp. 3164–3175, 2012.
[114] K. Kubota, M. Moriyama, S. Furukawa et al.,
“CD163+CD204+tumor-associated macrophages contribute
to T cell regulation via interleukin-10 and PD-L1 produc-
tion in oral squamous cell carcinoma,” Scientiﬁc Reports,
vol. 7, no. 1, p. 1755, 2017.
[115] G. Lenz, G. Wright, S. S. Dave et al., “Stromal gene signatures
in large-B-cell lymphomas,” The New England Journal of
Medicine, vol. 359, no. 22, pp. 2313–2323, 2008.
[116] M. Liguori, G. Solinas, G. Germano, A. Mantovani, and
P. Allavena, “Tumor-associated macrophages as incessant
builders and destroyers of the cancer stroma,” Cancer,
vol. 3, no. 4, pp. 3740–3761, 2011.
[117] F. T. Andon, E. Digiﬁco, A. Maeda et al., “Targeting tumor
associated macrophages: the new challenge for nanomedi-
cine,” Seminars in Immunology, 2017.
[118] A. Mantovani, F. Marchesi, A. Malesci, L. Laghi, and
P. Allavena, “Tumour-associated macrophages as treatment
targets in oncology,” Nature Reviews Clinical Oncology,
vol. 14, no. 7, pp. 399–416, 2017.
[119] S. M. Pyonteck, L. Akkari, A. J. Schuhmacher et al., “CSF-1R
inhibition alters macrophage polarization and blocks gli-
oma progression,” Nature Medicine, vol. 19, no. 10,
pp. 1264–1272, 2013.
[120] C. H. Ries, M. A. Cannarile, S. Hoves et al., “Targeting tumor-
associated macrophages with anti-CSF-1R antibody reveals a
strategy for cancer therapy,” Cancer Cell, vol. 25, no. 6,
pp. 846–859, 2014.
[121] X. Zheng, K. Turkowski, J. Mora et al., “Redirecting tumor-
associated macrophages to become tumoricidal eﬀectors as
a novel strategy for cancer therapy,” Oncotarget, vol. 8,
no. 29, pp. 48436–48452, 2017.
[122] X. Li, W. Yao, Y. Yuan et al., “Targeting of tumour-
inﬁltrating macrophages via CCL2/CCR2 signalling as a ther-
apeutic strategy against hepatocellular carcinoma,” Gut,
vol. 66, no. 1, pp. 157–167, 2017.
[123] R. D. Loberg, C. Ying, M. Craig et al., “Targeting CCL2 with
systemic delivery of neutralizing antibodies induces prostate
cancer tumor regression in vivo,” Cancer Research, vol. 67,
no. 19, pp. 9417–9424, 2007.
[124] L. Bonapace, M. M. Coissieux, J. Wyckoﬀ et al., “Cessation of
CCL2 inhibition accelerates breast cancer metastasis by pro-
moting angiogenesis,” Nature, vol. 515, no. 7525, pp. 130–
133, 2014.
[125] N. Halama, I. Zoernig, A. Berthel et al., “Tumoral immune
cell exploitation in colorectal cancer metastases can be tar-
geted eﬀectively by anti-CCR5 therapy in cancer patients,”
Cancer Cell, vol. 29, no. 4, pp. 587–601, 2016.
[126] S. Junankar, G. Shay, J. Jurczyluk et al., “Real-time intravital
imaging establishes tumor-associated macrophages as the
extraskeletal target of bisphosphonate action in cancer,” Can-
cer Discovery, vol. 5, no. 1, pp. 35–42, 2015.
[127] H. H. Van Acker, S. Anguille, Y. Willemen, E. L. Smits,
and V. F. van Tendeloo, “Bisphosphonates for cancer
treatment: mechanisms of action and lessons from clinical
trials,” Pharmacology & Therapeutics, vol. 158, pp. 24–40,
2016.
[128] G. L. Beatty, E. G. Chiorean, M. P. Fishman et al., “CD40 ago-
nists alter tumor stroma and show eﬃcacy against pancreatic
carcinoma in mice and humans,” Science, vol. 331, no. 6024,
pp. 1612–1616, 2011.
[129] G. L. Beatty, D. A. Torigian, E. G. Chiorean et al., “A phase I
study of an agonist CD40 monoclonal antibody (CP-870,893)
in combination with gemcitabine in patients with advanced
pancreatic ductal adenocarcinoma,”Clinical Cancer Research,
vol. 19, no. 22, pp. 6286–6295, 2013.
[130] P. Allavena, G. Germano, C. Belgiovine, M. D’Incalci, and
A. Mantovani, “Trabectedin: a drug from the sea that strikes
tumor-associated macrophages,” OncoImmunology, vol. 2,
no. 6, article e24614, 2013.
[131] G. Germano, R. Frapolli, C. Belgiovine et al., “Role of macro-
phage targeting in the antitumor activity of trabectedin,”
Cancer Cell, vol. 23, no. 2, pp. 249–262, 2013.
[132] H. L. Kammoun, M. J. Kraakman, and M. A. Febbraio, “Adi-
pose tissue inﬂammation in glucose metabolism,” Reviews in
Endocrine and Metabolic Disorders, vol. 15, no. 1, pp. 31–44,
2014.
[133] A. Chawla, K. D. Nguyen, and Y. P. S. Goh, “Macrophage-
mediated inﬂammation in metabolic disease,” Nature
Reviews Immunology, vol. 11, no. 11, pp. 738–749, 2011.
[134] G. S. Hotamisligil, “Inﬂammation and metabolic disorders,”
Nature, vol. 444, no. 7121, pp. 860–867, 2006.
[135] J. G. Neels and J. M. Olefsky, “Inﬂamed fat: what starts the
ﬁre?,” The Journal of Clinical Investigation, vol. 116, no. 1,
pp. 33–35, 2006.
20 Journal of Immunology Research
[136] S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L.
Leibel, and A. W. Ferrante Jr., “Obesity is associated with
macrophage accumulation in adipose tissue,” The Journal of
Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003.
[137] X. Xiao and G. K. Gittes, “Concise review: new insights into
the role of macrophages in β-cell proliferation,” Stem Cells
Translational Medicine, vol. 4, no. 6, pp. 655–658, 2015.
[138] X. Cao, Z. B. Han, H. Zhao, and Q. Liu, “Transplantation of
mesenchymal stem cells recruits trophic macrophages to
induce pancreatic beta cell regeneration in diabetic mice,”
The International Journal of Biochemistry & Cell Biology,
vol. 53, pp. 372–379, 2014.
[139] N. Van Gassen, E. van Overmeire, G. Leuckx et al., “Macro-
phage dynamics are regulated by local macrophage prolifera-
tion and monocyte recruitment in injured pancreas,”
European Journal of Immunology, vol. 45, no. 5, pp. 1482–
1493, 2015.
[140] X. Xiao, I. Gaﬀar, P. Guo et al., “M2 macrophages promote
beta-cell proliferation by up-regulation of SMAD7,” Proceed-
ings of the National Academy of Sciences of the United States
of America, vol. 111, no. 13, pp. E1211–E1220, 2014.
[141] X. Xiao, J. Wiersch, Y. El-Gohary et al., “TGFβ receptor sig-
naling is essential for inﬂammation-induced but not β-cell
workload-induced β-cell proliferation,” Diabetes, vol. 62,
no. 4, pp. 1217–1226, 2013.
[142] K. Eguchi, I. Manabe, Y. Oishi-Tanaka et al., “Saturated fatty
acid and TLR signaling link β cell dysfunction and islet
inﬂammation,” Cell Metabolism, vol. 15, no. 4, pp. 518–533,
2012.
[143] H. Cucak, L. G. Grunnet, and A. Rosendahl, “Accumulation
of M1-like macrophages in type 2 diabetic islets is followed
by a systemic shift in macrophage polarization,” Journal of
Leukocyte Biology, vol. 95, no. 1, pp. 149–160, 2014.
[144] A. Espinoza-Jimenez, A. N. Peon, and L. I. Terrazas, “Alter-
natively activated macrophages in types 1 and 2 diabetes,”
Mediators of Inﬂammation, vol. 2012, Article ID 815953,
p. 10, 2012.
[145] C. N. Lumeng, J. L. Bodzin, and A. R. Saltiel, “Obesity induces
a phenotypic switch in adipose tissue macrophage polariza-
tion,” The Journal of Clinical Investigation, vol. 117, no. 1,
pp. 175–184, 2007.
[146] A. Nawaz, A. Aminuddin, T. Kado et al., “CD206+ M2-like
macrophages regulate systemic glucose metabolism by inhi-
biting proliferation of adipocyte progenitors,” Nature Com-
munications, vol. 8, no. 1, p. 286, 2017.
[147] J. M. Olefsky and C. K. Glass, “Macrophages, inﬂammation,
and insulin resistance,” Annual Review of Physiology,
vol. 72, no. 1, pp. 219–246, 2010.
[148] M. Y. Donath and S. E. Shoelson, “Type 2 diabetes as an
inﬂammatory disease,” Nature Reviews Immunology, vol. 11,
no. 2, pp. 98–107, 2011.
[149] U. Jung andM.-S. Choi, “Obesity and its metabolic complica-
tions: the role of adipokines and the relationship between
obesity, inﬂammation, insulin resistance, dyslipidemia and
nonalcoholic fatty liver disease,” International Journal of
Molecular Sciences, vol. 15, no. 4, pp. 6184–6223, 2014.
[150] S. Nakajima, V. Koh, L. F. Kua et al., “Accumulation of
CD11c+CD163+ adipose tissue macrophages through
upregulation of intracellular 11β-HSD1 in human obesity,”
The Journal of Immunology, vol. 197, no. 9, pp. 3735–3745,
2016.
[151] A. Takikawa, A. Mahmood, A. Nawaz et al., “HIF-1α in
myeloid cells promotes adipose tissue remodeling toward
insulin resistance,” Diabetes, vol. 65, no. 12, pp. 3649–
3659, 2016.
[152] M. Zeyda and T. M. Stulnig, “Adipose tissue macrophages,”
Immunology Letters, vol. 112, no. 2, pp. 61–67, 2007.
[153] A. Bouloumie, C. A. Curat, C. Sengenès, K. Lolmède,
A. Miranville, and R. Busse, “Role of macrophage tissue inﬁl-
tration in metabolic diseases,” Current Opinion in Clinical
Nutrition and Metabolic Care, vol. 8, no. 4, pp. 347–354,
2005.
[154] J. I. Odegaard, R. R. Ricardo-Gonzalez, A. Red Eagle et al.,
“Alternative M2 activation of Kupﬀer cells by PPARδ amelio-
rates obesity-induced insulin resistance,” Cell Metabolism,
vol. 7, no. 6, pp. 496–507, 2008.
[155] J. I. Odegaard and A. Chawla, “Mechanisms of macrophage
activation in obesity-induced insulin resistance,” Nature
Clinical Practice Endocrinology & Metabolism, vol. 4, no. 11,
pp. 619–626, 2008.
[156] J. I. Odegaard, R. R. Ricardo-Gonzalez, M. H. Goforth et al.,
“Macrophage-speciﬁc PPARγ controls alternative activation
and improves insulin resistance,” Nature, vol. 447, no. 7148,
pp. 1116–1120, 2007.
[157] N. Halberg, I. Wernstedt-Asterholm, and P. E. Scherer, “The
adipocyte as an endocrine cell,” Endocrinology and Metabo-
lism Clinics of North America, vol. 37, no. 3, pp. 753–768,
2008.
[158] P. E. Scherer, “Adipose tissue: from lipid storage compartment
to endocrine organ,” Diabetes, vol. 55, no. 6, pp. 1537–1545,
2006.
[159] A. Chen, S. Mumick, C. Zhang et al., “Diet induction of
monocyte chemoattractant protein-1 and its impact on obe-
sity,” Obesity Research, vol. 13, no. 8, pp. 1311–1320, 2005.
[160] S. P. Weisberg, D. Hunter, R. Huber et al., “CCR2 modulates
inﬂammatory and metabolic eﬀects of high-fat feeding,” The
Journal of Clinical Investigation, vol. 116, no. 1, pp. 115–124,
2006.
[161] G. S. Hotamisligil, P. Arner, J. F. Caro, R. L. Atkinson, and
B. M. Spiegelman, “Increased adipose tissue expression of
tumor necrosis factor-alpha in human obesity and insulin
resistance,” The Journal of Clinical Investigation, vol. 95,
no. 5, pp. 2409–2415, 1995.
[162] S. I. Itani, N. B. Ruderman, F. Schmieder, and G. Boden,
“Lipid-induced insulin resistance in human muscle is associ-
ated with changes in diacylglycerol, protein kinase C, and
IκB-α,” Diabetes, vol. 51, no. 7, pp. 2005–2011, 2002.
[163] M. S. Han, D. Y. Jung, C. Morel et al., “JNK expression by
macrophages promotes obesity-induced insulin resistance
and inﬂammation,” Science, vol. 339, no. 6116, pp. 218–222,
2013.
[164] T. Jourdan, G. Godlewski, R. Cinar et al., “Activation of the
Nlrp3 inﬂammasome in inﬁltrating macrophages by endo-
cannabinoids mediates beta cell loss in type 2 diabetes,”
Nature Medicine, vol. 19, no. 9, pp. 1132–1140, 2013.
[165] R. Menghini, V. Casagrande, S. Menini et al., “TIMP3 overex-
pression in macrophages protects from insulin resistance,
adipose inﬂammation, and nonalcoholic fatty liver disease
in mice,” Diabetes, vol. 61, no. 2, pp. 454–462, 2012.
[166] B. Desvergne, “PPARδ/β: the lobbyist switching macrophage
allegiance in favor of metabolism,” Cell Metabolism, vol. 7,
no. 6, pp. 467–469, 2008.
21Journal of Immunology Research
[167] M. Zhang, Z. Zhou, J. Wang, and S. Li, “MiR-130b promotes
obesity associated adipose tissue inﬂammation and insulin
resistance in diabetes mice through alleviating M2 macro-
phage polarization via repression of PPAR-γ,” Immunology
Letters, vol. 180, pp. 1–8, 2016.
[168] O. M. Finucane, C. M. Reynolds, F. C. McGillicuddy, and
H. M. Roche, “Insights into the role of macrophage migration
inhibitory factor in obesity and insulin resistance,” Proceed-
ings of the Nutrition Society, vol. 71, no. 4, pp. 622–633, 2012.
[169] J. Braune, U. Weyer, C. Hobusch et al., “IL-6 regulates M2
polarization and local proliferation of adipose tissue macro-
phages in obesity,” The Journal of Immunology, vol. 198,
no. 7, pp. 2927–2934, 2017.
[170] S. Galic, M. D. Fullerton, J. D. Schertzer et al., “Hematopoietic
AMPK β1 reduces mouse adipose tissue macrophage inﬂam-
mation and insulin resistance in obesity,” The Journal of
Clinical Investigation, vol. 121, no. 12, pp. 4903–4915, 2011.
[171] I. J. H. Duncan, “Designing environments for animals—not
for public perceptions,” British Veterinary Journal, vol. 148,
no. 6, pp. 475–477, 1992.
[172] G. S. Hotamisligil, “Inﬂammatory pathways and insulin
action,” International Journal of Obesity, vol. 27, Supplement
3, pp. S53–S55, 2003.
[173] G. Bleau and M. Desaulniers, “High-performance liquid
chromatographic assay of benzalkonium in plasma,” Journal
of Chromatography B: Biomedical Sciences and Applications,
vol. 487, no. 1, pp. 221–227, 1989.
[174] C. A. Dinarello, M. Y. Donath, and T. Mandrup-Poulsen,
“Role of IL-1β in type 2 diabetes,” Current Opinion in Endo-
crinology, Diabetes, and Obesity, vol. 17, no. 4, pp. 314–321,
2010.
[175] C. M. Larsen, M. Faulenbach, A. Vaag et al., “Interleukin-1-
receptor antagonist in type 2 diabetes mellitus,” The New
England Journal of Medicine, vol. 356, no. 15, pp. 1517–
1526, 2007.
[176] G. R. Thurnau, D. H. Scates, and M. A. Morgan, “The
fetal-pelvic index: a method of identifying fetal-pelvic dis-
proportion in women attempting vaginal birth after previ-
ous cesarean delivery,” American Journal of Obstetrics &
Gynecology, vol. 165, no. 2, pp. 353–358, 1991.
[177] A. Ito, T. Suganami, A. Yamauchi et al., “Role of CC che-
mokine receptor 2 in bone marrow cells in the recruitment
of macrophages into obese adipose tissue,” The Journal of
Biological Chemistry, vol. 283, no. 51, pp. 35715–35723,
2008.
[178] D. Y. Oh, H. Morinaga, S. Talukdar, E. J. Bae, and J. M.
Olefsky, “Increased macrophage migration into adipose tis-
sue in obese mice,”Diabetes, vol. 61, no. 2, pp. 346–354, 2012.
[179] M. Saberi, N. B. Woods, C. de Luca et al., “Hematopoietic
cell-speciﬁc deletion of toll-like receptor 4 ameliorates
hepatic and adipose tissue insulin resistance in high-fat-
fed mice,” Cell Metabolism, vol. 10, no. 5, pp. 419–429,
2009.
[180] H. Shi, M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J. S.
Flier, “TLR4 links innate immunity and fatty acid-induced
insulin resistance,” The Journal of Clinical Investigation,
vol. 116, no. 11, pp. 3015–3025, 2006.
[181] D. M. L. Tsukumo, M. A. Carvalho-Filho, J. B. C. Carvalheira
et al., “Loss-of-function mutation in toll-like receptor 4 pre-
vents diet-induced obesity and insulin resistance,” Diabetes,
vol. 56, no. 8, pp. 1986–1998, 2007.
[182] P. Mancuso, “The role of adipokines in chronic inﬂamma-
tion,” ImmunoTargets and Therapy, vol. 5, pp. 47–56,
2016.
[183] M. Qatanani, N. R. Szwergold, D. R. Greaves, R. S. Ahima,
and M. A. Lazar, “Macrophage-derived human resistin exac-
erbates adipose tissue inﬂammation and insulin resistance in
mice,” The Journal of Clinical Investigation, vol. 119, no. 3,
pp. 531–539, 2009.
[184] T. Suganami, J. Nishida, and Y. Ogawa, “A paracrine loop
between adipocytes and macrophages aggravates inﬂamma-
tory changes: role of free fatty acids and tumor necrosis
factor α,” Arteriosclerosis, Thrombosis, and Vascular Biol-
ogy, vol. 25, no. 10, pp. 2062–2068, 2005.
[185] F. A. Lainson, D. C. Harkins, C. F. Wilson et al., “Identiﬁca-
tion and localization of an iron-regulated 35 kDa protein of
Pasteurella haemolytica serotype A2,” Journal of General
Microbiology, vol. 137, no. 2, pp. 219–226, 1991.
[186] A. Consoli and G. Formoso, “Do thiazolidinediones still have
a role in treatment of type 2 diabetes mellitus?,” Diabetes,
Obesity and Metabolism, vol. 15, no. 11, pp. 967–977, 2013.
[187] A. L. Hevener, J. M. Olefsky, D. Reichart et al., “Macrophage
PPARγ is required for normal skeletal muscle and hepatic
insulin sensitivity and full antidiabetic eﬀects of thiazolidine-
diones,” The Journal of Clinical Investigation, vol. 117, no. 6,
pp. 1658–1669, 2007.
[188] Y. Hattori, K. Hattori, and T. Hayashi, “Pleiotropic beneﬁts of
metformin: macrophage targeting its anti-inﬂammatory
mechanisms,” Diabetes, vol. 64, no. 6, pp. 1907–1909, 2015.
[189] W. Ohashi, K. Hattori, and Y. Hattori, “Control of macro-
phage dynamics as a potential therapeutic approach for clin-
ical disorders involving chronic inﬂammation,” The Journal
of Pharmacology and Experimental Therapeutics, vol. 354,
no. 3, pp. 240–250, 2015.
[190] M. Feldman, I. Jialal, S. Devaraj, and B. Cryer, “Eﬀects of
low-dose aspirin on serum C-reactive protein and throm-
boxane B2concentrations: a placebo-controlled study using
a highly sensitive C-reactive protein assay,” Journal of the
American College of Cardiology, vol. 37, no. 8, pp. 2036–
2041, 2001.
[191] M. C. P. Sok, M. C. Tria, C. E. Olingy, C. L. San Emeterio, and
E. A. Botchwey, “Aspirin-triggered resolvin D1-modiﬁed
materials promote the accumulation of pro-regenerative
immune cell subsets and enhance vascular remodeling,” Acta
Biomaterialia, vol. 53, pp. 109–122, 2017.
[192] A. Chaudhuri, H. Ghanim, M. Vora et al., “Exenatide exerts a
potent antiinﬂammatory eﬀect,” The Journal of Clinical
Endocrinology & Metabolism, vol. 97, no. 1, pp. 198–207,
2012.
[193] M. Ferdaoussi, S. Abdelli, J. Y. Yang et al., “Exendin-4 pro-
tects β-cells from interleukin-1β-induced apoptosis by inter-
fering with the c-Jun NH2-terminal kinase pathway,”
Diabetes, vol. 57, no. 5, pp. 1205–1215, 2008.
[194] H. F. Lodish, B. Zhou, G. Liu, and C. Z. Chen, “Microman-
agement of the immune system by microRNAs,” Nature
Reviews Immunology, vol. 8, no. 2, pp. 120–130, 2008.
[195] G. Zhuang, C. Meng, X. Guo et al., “A novel regulator of
macrophage activation: miR-223 in obesity-associated adi-
pose tissue inﬂammation,” Circulation, vol. 125, no. 23,
pp. 2892–2903, 2012.
[196] F. Yao, Y. Yu, L. Feng et al., “Adipogenic miR-27a in adipose
tissue upregulates macrophage activation via inhibiting
22 Journal of Immunology Research
PPARγ of insulin resistance induced by high-fat diet-
associated obesity,” Experimental Cell Research, vol. 355,
no. 2, pp. 105–112, 2017.
[197] C. Weber and H. Noels, “Atherosclerosis: current pathogene-
sis and therapeutic options,” Nature Medicine, vol. 17, no. 11,
pp. 1410–1422, 2011.
[198] K. J. Moore and I. Tabas, “Macrophages in the pathogenesis
of atherosclerosis,” Cell, vol. 145, no. 3, pp. 341–355, 2011.
[199] L. E. Viiri, L. E. Full, T. J. Navin et al., “Smooth muscle cells in
human atherosclerosis: proteomic proﬁling reveals diﬀer-
ences in expression of annexin A1 and mitochondrial pro-
teins in carotid disease,” Journal of Molecular and Cellular
Cardiology, vol. 54, pp. 65–72, 2013.
[200] A. R. Tall, P. Costet, and N. Wang, “Regulation and mecha-
nisms of macrophage cholesterol eﬄux,” The Journal of Clin-
ical Investigation, vol. 110, no. 7, pp. 899–904, 2002.
[201] T. A. Seimon, M. J. Nadolski, X. Liao et al., “Atherogenic
lipids and lipoproteins trigger CD36-TLR2-dependent apo-
ptosis in macrophages undergoing endoplasmic reticulum
stress,” Cell Metabolism, vol. 12, no. 5, pp. 467–482, 2010.
[202] G. Chinetti-Gbaguidi, S. Colin, and B. Staels, “Macrophage
subsets in atherosclerosis,” Nature Reviews Cardiology,
vol. 12, no. 1, pp. 10–17, 2015.
[203] P. Duewell, H. Kono, K. J. Rayner et al., “NLRP3 inﬂamma-
somes are required for atherogenesis and activated by choles-
terol crystals,”Nature, vol. 464, no. 7293, pp. 1357–1361, 2010.
[204] K. Hirose, K. Iwabuchi, K. Shimada et al., “Diﬀerent responses
to oxidized low-density lipoproteins in human polarizedmac-
rophages,” Lipids in Health and Disease, vol. 10, no. 1, p. 1,
2011.
[205] L. J. H. van Tits, R. Stienstra, P. L. van Lent, M. G. Netea, L. A.
B. Joosten, and A. F. H. Stalenhoef, “Oxidized LDL enhances
pro-inﬂammatory responses of alternatively activated M2
macrophages: a crucial role for Krüppel-like factor 2,” Ath-
erosclerosis, vol. 214, no. 2, pp. 345–349, 2011.
[206] Y. S. Bae, J. H. Lee, S. H. Choi et al., “Macrophages generate
reactive oxygen species in response to minimally oxidized
low-density lipoprotein: toll-like receptor 4- and spleen tyro-
sine kinase-dependent activation of NADPH oxidase 2,” Cir-
culation Research, vol. 104, no. 2, pp. 210–218, 2009.
[207] B. Sottero, P. Gamba, M. Longhi et al., “Expression and
synthesis of TGFβ1 is induced in macrophages by 9-
oxononanoyl cholesterol, a major cholesteryl ester oxidation
product,” BioFactors, vol. 24, no. 1–4, pp. 209–216, 2005.
[208] J. E. Hughes, S. Srinivasan, K. R. Lynch, R. L. Proia, P. Ferdek,
and C. C. Hedrick, “Sphingosine-1-phosphate induces an
antiinﬂammatory phenotype in macrophages,” Circulation
Research, vol. 102, no. 8, pp. 950–8, 2008.
[209] S. Adamson and N. Leitinger, “Phenotypic modulation of
macrophages in response to plaque lipids,” Current Opinion
in Lipidology, vol. 22, no. 5, pp. 335–342, 2011.
[210] S. Colin, G. Chinetti-Gbaguidi, and B. Staels, “Macrophage
phenotypes in atherosclerosis,” Immunological Reviews,
vol. 262, no. 1, pp. 153–166, 2014.
[211] F. De Paoli, B. Staels, and G. Chinetti-Gbaguidi, “Macro-
phage phenotypes and their modulation in atherosclerosis,”
Circulation Journal, vol. 78, no. 8, pp. 1775–1781, 2014.
[212] A. Kadl, A. K. Meher, P. R. Sharma et al., “Identiﬁcation of a
novel macrophage phenotype that develops in response to
atherogenic phospholipids via Nrf2,” Circulation Research,
vol. 107, no. 6, pp. 737–746, 2010.
[213] Y. Naito, T. Takagi, and Y. Higashimura, “Heme oxygenase-1
and anti-inﬂammatory M2 macrophages,” Archives of Bio-
chemistry and Biophysics, vol. 564, pp. 83–88, 2014.
[214] A.Kadl, P. R. Sharma,W.Chen et al., “Oxidized phospholipid-
induced inﬂammation is mediated by Toll-like receptor 2,”
Free Radical Biology & Medicine, vol. 51, no. 10, pp. 1903–
1909, 2011.
[215] F. K. Swirski, P. Libby, E. Aikawa et al., “Ly-6Chi monocytes
dominate hypercholesterolemia-associated monocytosis and
give rise to macrophages in atheromata,” The Journal of Clin-
ical Investigation, vol. 117, no. 1, pp. 195–205, 2007.
[216] M. de Gaetano, D. Crean, M. Barry, and O. Belton, “M1- and
M2-type macrophage responses are predictive of adverse out-
comes in human atherosclerosis,” Frontiers in Immunology,
vol. 7, p. 275, 2016.
[217] K. J. Moore, F. J. Sheedy, and E. A. Fisher, “Macrophages in
atherosclerosis: a dynamic balance,” Nature Reviews Immu-
nology, vol. 13, no. 10, pp. 709–721, 2013.
[218] H. M.Wilson, “Macrophages heterogeneity in atherosclerosis
- implications for therapy,” Journal of Cellular and Molecular
Medicine, vol. 14, no. 8, pp. 2055–2065, 2010.
[219] L. Bai, Z. Li, Q. Li et al., “Mediator 1 is atherosclerosis protec-
tive by regulating macrophage polarization,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 37, no. 8, pp. 1470–
1481, 2017.
[220] J. H. Choi, J. G. Park, H. J. Jeon et al., “5-(4-Hydroxy-2,3,5-
trimethylbenzylidene) thiazolidine-2,4-dione attenuates ath-
erosclerosis possibly by reducing monocyte recruitment to
the lesion,” Experimental & Molecular Medicine, vol. 43,
no. 8, pp. 471–8, 2011.
[221] S. B. Joseph, A. Castrillo, B. A. Laﬃtte, D. J. Mangelsdorf, and
P. Tontonoz, “Reciprocal regulation of inﬂammation and
lipid metabolism by liver X receptors,” Nature Medicine,
vol. 9, no. 2, pp. 213–219, 2003.
[222] R. K. Tangirala, E. D. Bischoﬀ, S. B. Joseph et al., “Identiﬁca-
tion of macrophage liver X receptors as inhibitors of athero-
sclerosis,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 99, no. 18, pp. 11896–
11901, 2002.
[223] J. R. Nofer, M. Bot, M. Brodde et al., “FTY720, a synthetic
sphingosine 1 phosphate analogue, inhibits development of
atherosclerosis in low-density lipoprotein receptor–deﬁcient
mice,” Circulation, vol. 115, no. 4, pp. 501–508, 2007.
[224] K. Morimoto, W. J. Janssen, M. B. Fessler et al., “Lovastatin
enhances clearance of apoptotic cells (eﬀerocytosis) with
implications for chronic obstructive pulmonary disease,”
The Journal of Immunology, vol. 176, no. 12, pp. 7657–7665,
2006.
[225] I. Sergin, T. D. Evans, X. Zhang et al., “Exploiting macro-
phage autophagy-lysosomal biogenesis as a therapy for ath-
erosclerosis,” Nature Communications, vol. 8, article 15750,
2017.
[226] Y. H. Ding, L. Y. Qian, J. Pang et al., “The regulation of
immune cells by Lactobacilli: a potential therapeutic target
for anti-atherosclerosis therapy,” Oncotarget, vol. 8, no. 35,
pp. 59915–59928, 2017.
[227] R. C. Page and H. E. Schroeder, “Pathogenesis of inﬂamma-
tory periodontal disease. A summary of current work,” Labo-
ratory Investigation, vol. 34, no. 3, pp. 235–249, 1976.
[228] C. C. Chapple, M. Srivastava, and N. Hunter, “Failure of
macrophage activation in destructive periodontal disease,”
23Journal of Immunology Research
The Journal of Pathology, vol. 186, no. 3, pp. 281–286,
1998.
[229] R. C. Page, “The role of inﬂammatory mediators in the path-
ogenesis of periodontal disease,” Journal of Periodontal
Research, vol. 26, no. 3, pp. 230–242, 1991.
[230] R. Assuma, T. Oates, D. Cochran, S. Amar, and D. T. Graves,
“IL-1 and TNF antagonists inhibit the inﬂammatory response
and bone loss in experimental periodontitis,” The Journal of
Immunology, vol. 160, no. 1, pp. 403–409, 1998.
[231] V. I. Haraszthy, J. J. Zambon, M. Trevisan, M. Zeid, and R. J.
Genco, “Identiﬁcation of periodontal pathogens in atheroma-
tous plaques,” Journal of Periodontology, vol. 71, no. 10,
pp. 1554–1560, 2000.
[232] L. Li, E. Messas, E. L. Batista, R. A. Levine, and S. Amar, “Por-
phyromonas gingivalis infection accelerates the progression of
atherosclerosis in a heterozygous apolipoprotein E-deﬁcient
murine model,” Circulation, vol. 105, no. 7, pp. 861–7, 2002.
[233] S. Seguier, B. Gogly, A. Bodineau, G. Godeau, and N. Brousse,
“Is collagen breakdown during periodontitis linked to inﬂam-
matory cells and expression of matrix metalloproteinases and
tissue inhibitors of metalloproteinases in human gingival tis-
sue?,” Journal of Periodontology, vol. 72, no. 10, pp. 1398–
1406, 2001.
[234] R. A. Kayal, “The role of osteoimmunology in periodontal
disease,” BioMed Research International, vol. 2013, Article
ID 639368, 12 pages, 2013.
[235] T. N. Crotti, A. A. Dharmapatni, E. Alias, and D. R. Haynes,
“Osteoimmunology: major and costimulatory pathway
expression associated with chronic inﬂammatory induced
bone loss,” Journal of Immunology Research, vol. 2015, Arti-
cle ID 281287, 13 pages, 2015.
[236] J. Charon, P. D. Toto, and A. W. Gargiulo, “Activated macro-
phages in human periodontitis,” Journal of Periodontology,
vol. 52, no. 6, pp. 328–335, 1981.
[237] S. Hanazawa, A. Takeshita, S. Amano et al., “Tumor necrosis
factor-α induces expression of monocyte chemoattractant JE
via fos and jun genes in clonal osteoblastic MC3T3-E1 cells,”
Journal of Biological Chemistry, vol. 268, no. 13, pp. 9526–
9532, 1993.
[238] A. Mathur, B. Michalowicz, M. Castillo, and D. Aeppll,
“Interleukin-1 alpha, interleukin-8 and interferon-alpha
levels in gingival crevicular ﬂuid,” Journal of Periodontal
Research, vol. 31, no. 7, pp. 489–495, 1996.
[239] G. Hajishengallis, R. P. Darveau, and M. A. Curtis, “The
keystone-pathogen hypothesis,” Nature Reviews Microbiol-
ogy, vol. 10, no. 10, pp. 717–725, 2012.
[240] S. S. Socransky, A. D. Haﬀajee, M. A. Cugini, C. Smith, and
R. L. Kent, “Microbial complexes in subgingival plaque,”
Journal of Clinical Periodontology, vol. 25, no. 2, pp. 134–
144, 1998.
[241] F. C. Nichols, B. Bajrami, R. B. Clark, W. Housley, and
X. Yao, “Free lipid A isolated from Porphyromonas gingivalis
lipopolysaccharide is contaminated with phosphorylated
dihydroceramide lipids: recovery in diseased dental samples,”
Infection and Immunity, vol. 80, no. 2, pp. 860–874, 2012.
[242] E. Burns, G. Bachrach, L. Shapira, and G. Nussbaum, “Cut-
ting edge: TLR2 is required for the innate response to
Porphyromonas gingivalis: activation leads to bacterial per-
sistence and TLR2 deﬁciency attenuates induced alveolar
bone resorption,” The Journal of Immunology, vol. 177,
no. 12, pp. 8296–8300, 2006.
[243] G. Hajishengallis, M. Wang, G. J. Bagby, and S. Nelson,
“Importance of TLR2 in early innate immune response to
acute pulmonary infection with Porphyromonas gingivalis in
mice,” The Journal of Immunology, vol. 181, no. 6,
pp. 4141–4149, 2008.
[244] O. Takeuchi, K. Hoshino, T. Kawai et al., “Diﬀerential roles of
TLR2 and TLR4 in recognition of gram-negative and gram-
positive bacterial cell wall components,” Immunity, vol. 11,
no. 4, pp. 443–451, 1999.
[245] G. Papadopoulos, E. O. Weinberg, P. Massari et al., “Macro-
phage-speciﬁc TLR2 signaling mediates pathogen-induced
TNF-dependent inﬂammatory oral bone loss,” The Journal
of Immunology, vol. 190, no. 3, pp. 1148–1157, 2013.
[246] J. J. Jandinski, P. Stashenko, L. S. Feder et al., “Localization of
interleukin-1β in human periodontal tissue,” Journal of Peri-
odontology, vol. 62, no. 1, pp. 36–43, 1991.
[247] Y. Matsuki, T. Yamamoto, and K. Hara, “Detection of inﬂam-
matory cytokine messenger RNA (mRNA)-expressing cells in
human inﬂamed gingiva by combined in situ hybridization
and immunohistochemistry,” Immunology, vol. 76, no. 1,
pp. 42–47, 1992.
[248] S. Oﬀenbacher, V. Katz, G. Fertik et al., “Periodontal infec-
tion as a possible risk factor for preterm low birth weight,”
Journal of Periodontology, vol. 67, no. 10s, pp. 1103–1113,
1996.
[249] S. Oﬀenbacheer, B. M. Odle, and T. E. Van Dyke, “The use of
crevicular ﬂuid prostaglandin E2 levels as a predictor of peri-
odontal attachment loss,” Journal of Periodontal Research,
vol. 21, no. 2, pp. 101–112, 1986.
[250] D. Richards and R. B. Rutherford, “The eﬀects of interleukin
1 on collagenolytic activity and prostaglandin-e secretion by
human periodontal-ligament and gingival ﬁbroblast,”
Archives of Oral Biology, vol. 33, no. 4, pp. 237–243, 1988.
[251] D. R. Bertolini, G. E. Nedwin, T. S. Bringman, D. D. Smith,
and G. R. Mundy, “Stimulation of bone resorption and inhi-
bition of bone formation in vitro by human tumour necrosis
factors,” Nature, vol. 319, no. 6053, pp. 516–518, 1986.
[252] J. K. Health, J. Saklatvala, M. C. Meikle, S. J. Atkinson, and
J. J. Reynolds, “Pig interleukin 1 (catabolin) is a potent stim-
ulator of bone resorption in vitro,” Calciﬁed Tissue Interna-
tional, vol. 37, no. 1, pp. 95–97, 1985.
[253] K. D. Merkel, J. M. Erdmann, K. P. McHugh, Y. Abu-Amer,
F. P. Ross, and S. L. Teitelbaum, “Tumor necrosis factor-α
mediates orthopedic implant osteolysis,” The American Jour-
nal of Pathology, vol. 154, no. 1, pp. 203–210, 1999.
[254] R. S. Lam, N. M. O’Brien-Simpson, J. A. Holden, J. C.
Lenzo, S. B. Fong, and E. C. Reynolds, “Unprimed, M1
and M2 macrophages diﬀerentially interact with Porphyro-
monas gingivalis,” PLoS One, vol. 11, no. 7, article e0158629,
2016.
[255] R. S. Lam, N. M. O’Brien-Simpson, J. C. Lenzo et al., “Macro-
phage depletion abates Porphyromonas gingivalis-induced
alveolar bone resorption in mice,” The Journal of Immunol-
ogy, vol. 193, no. 5, pp. 2349–2362, 2014.
[256] V. Tam, N. M. O'Brien-Simpson, Y. Y. Chen, C. J. Sanderson,
B. Kinnear, and E. C. Reynolds, “The RgpA-Kgp proteinase-
adhesin complexes of Porphyromonas gingivalis inactivate
the Th2 cytokines interleukin-4 and interleukin-5,” Infection
and Immunity, vol. 77, no. 4, pp. 1451–1458, 2009.
[257] A. D. Foey, N. Habil, K. Al-Shaghdali, and S. J. Crean,
“Porphyromonas gingivalis-stimulated macrophage subsets
24 Journal of Immunology Research
exhibit diﬀerential induction and responsiveness to inter-
leukin-10,” Archives of Oral Biology, vol. 73, pp. 282–288,
2017.
[258] C. Chavrier, M. L. Couble, D. Hartmann, J. A. Grimaud, and
H. Magloire, “Immunohistochemical study of types I, III and
IV collagen in ﬁbrosis of diseased gingiva during chronic
periodontitis: a light and electronmicroscopic study,” Journal
of Periodontal Research, vol. 22, no. 1, pp. 29–36, 1987.
[259] H. Larjava, V. J. Uitto, M. Haapasalo, J. Heino, and
M. Vuento, “Fibronectin fragmentation induced by dental
plaque and Bacteroides gingivalis,” European Journal of Oral
Sciences, vol. 95, no. 4, pp. 308–314, 1987.
[260] S. T. Smiley, J. A. King, and W. W. Hancock, “Fibrinogen
stimulates macrophage chemokine secretion through toll-
like receptor 4,” The Journal of Immunology, vol. 167, no. 5,
pp. 2887–2894, 2001.
[261] R. P. Settem, K. Honma, and A. Sharma, “Neutrophil mobili-
zation by surface-glycan altered Th17-skewing bacteria miti-
gates periodontal pathogen persistence and associated
alveolar bone loss,” PLoS One, vol. 9, no. 9, article e108030,
2014.
[262] G. Posch, G. Sekot, V. Friedrich et al., “Glycobiology aspects
of the periodontal pathogen Tannerella forsythia,” Biomole-
cules, vol. 2, no. 4, pp. 467–482, 2012.
[263] G. Sekot, G. Posch, P. Messner et al., “Potential of the Tanner-
ella forsythia S-layer to delay the immune response,” Journal
of Dental Research, vol. 90, no. 1, pp. 109–114, 2011.
[264] M. Matsumoto, T. Tanaka, T. Kaisho et al., “A novel LPS-
inducible C-type lectin is a transcriptional target of NF-IL6
in macrophages,” The Journal of Immunology, vol. 163,
no. 9, pp. 5039–5048, 1999.
[265] S. Chinthamani, R. P. Settem, K. Honma, J. G. Kay, and
A. Sharma, “Macrophage inducible C-type lectin (Mincle)
recognizes glycosylated surface (S)-layer of the periodontal
pathogen Tannerella forsythia,” PLoS One, vol. 12, no. 3, arti-
cle e0173394, 2017.
[266] V. Cogoni, A. Morgan-Smith, J. C. Fenno, H. F. Jenkinson,
and D. Dymock, “Treponema denticola chymotrypsin-like
proteinase (CTLP) integrates spirochaetes within oral micro-
bial communities,” Microbiology, vol. 158, Part 3, pp. 759–
770, 2012.
[267] K. Kurniyati, W. Zhang, K. Zhang, and C. Li, “A surface-
exposed neuraminidase aﬀects complement resistance and
virulence of the oral spirochaete Treponema denticola,”
Molecular Microbiology, vol. 89, no. 5, pp. 842–856, 2013.
[268] J. C. Fenno and B. C. McBride, “Virulence factors of oral trep-
onemes,” Anaerobe, vol. 4, no. 1, pp. 1–17, 1998.
[269] G. Rosen, M. N. Sela, R. Naor, A. Halabi, V. Barak, and
L. Shapira, “Activation of murine macrophages by lipopro-
tein and lipooligosaccharide of Treponema denticola,” Infec-
tion and Immunity, vol. 67, no. 3, pp. 1180–1186, 1999.
[270] M. V. Thomas and D. A. Puleo, “Infection, inﬂammation,
and bone regeneration: a paradoxical relationship,” Journal
of Dental Research, vol. 90, no. 9, pp. 1052–1061, 2011.
[271] J. Ruby, K. Rehani, and M. Martin, “Treponema denticola
activates mitogen-activated protein kinase signal pathways
through Toll-like receptor 2,” Infection and Immunity,
vol. 75, no. 12, pp. 5763–5768, 2007.
[272] G. Huang, L. Z. Shi, and H. Chi, “Regulation of JNK and p38
MAPK in the immune system: signal integration, propaga-
tion and termination,” Cytokine, vol. 48, no. 3, pp. 161–169,
2009.
[273] S. Miyajima, K. Naruse, Y. Kobayashi et al., “Periodontitis-
activated monocytes/macrophages cause aortic inﬂamma-
tion,” Scientiﬁc Reports, vol. 4, p. 5171, 2014.
25Journal of Immunology Research
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
